

# Remdesivir for COVID-19: real-time meta analysis of 67 studies

@CovidAnalysis, March 2024, Version 86  
<https://c19early.org/smeta.html>

## Abstract

Meta analysis shows 7% [-1-14%] lower mortality, and pooled analysis using the most serious outcome reported shows 6% [-1-12%] lower risk, without reaching statistical significance.

While studies to date show a small mortality improvement, meta regression with followup duration shows that this efficacy disappears with longer followup. There is also no benefit seen for mechanical ventilation, ICU admission, hospitalization, or progression. This may reflect antiviral efficacy being offset by side effects of treatment.

Studies show significantly increased risk of acute kidney injury


*Gérard, Wu, Zhou*

Prescription treatments have been preferentially used by patients at lower risk *Wilcock*. Retrospective studies may overestimate efficacy, for example patients with greater knowledge of effective treatments may be more likely to access prescription treatments but result in confounding because they are also more likely to use known beneficial non-prescription treatments.


No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments are significantly more effective.

All data to reproduce this paper and sources are in the appendix.

## Remdesivir for COVID-19



## Remdesivir mortality efficacy disappears with longer followup



## HIGHLIGHTS

Remdesivir shows a small mortality improvement, however this is primarily from studies with short followup duration, and efficacy declines with extended followup.

We show traditional outcome specific analyses and combined evidence from all studies, incorporating treatment delay, a primary confounding factor in COVID-19 studies.

Real-time updates and corrections, transparent analysis with all results in the same format, consistent protocol for 66 treatments.

# Remdesivir COVID-19 studies

c19early.org


March 2024


	Improvement, RR [CI]	Treatment	Control
Madan (ES)	66% 0.34 [0.12-0.96]	death 4/112	27/260
Gottlieb (DB RCT)	87% 0.13 [0.03-0.59]	death/hosp. 2/279	15/283
Piccicaccho	66% 0.34 [0.01-8.32]	death 0/82	1/90
Kneidinger	20% 0.80 [0.35-1.82]	severe case 6/46	28/172
Ong	-75% 1.75 [0.23-13.0]	recov. time 4 (n)	14 (n)
Chew	-68% 1.68 [0.51-5.58]	progression 12 (n)	151 (n)
Jittamala (RCT)	66% 0.34 [0.01-8.12]	hosp. 0/67	1/69
Seah	-129% 2.29 [0.26-20.1]	no recov. 2/7	1/8

**Early treatment 35%** 0.65 [0.33-1.29] 14/609 73/1,047

Tau<sup>2</sup> = 0.34, I<sup>2</sup> = 38.5%, p = 0.22

	Improvement, RR [CI]	Treatment	Control
Wang (RCT)	-9% 1.09 [0.54-2.18]	death 22/158	10/78
Olender	59% 0.41 [0.24-0.71]	death 24/312	102/818
Spinner (RCT)	35% 0.65 [0.18-2.40]	death 5/384	4/200
Pasquini (ICU)	16% 0.84 [0.69-0.94]	death 14/25	24/26
Fried	61% 0.39 [0.15-0.99]	death 4/48	2,510/11,673
Beigel (RCT)	27% 0.73 [0.52-1.03]	death 541 (n)	521 (n)
SOLIDARITY .. (RCT)	5% 0.95 [0.81-1.11]	death 301/2,743	303/2,708
El-Solh	29% 0.71 [0.52-0.97]	death 63/219	202/424
Flisiak	49% 0.51 [0.19-1.30]	death 5/122	17/211
Garibaldi	20% 0.80 [0.46-1.41]	death 23/303	45/303
Ullah	-100% 2.00 [0.67-5.94]	death 8/30	4/30
Yeramaneni	-24% 1.24 [0.11-14.2]	death 32 (n)	7,126 (n)
Goldberg	9% 0.91 [0.50-1.67]	hosp. time 29 (n)	113 (n)
Tsuzuki	-4% 1.04 [0.98-1.09]	death 69/824	285/11,663
Mahajan (RCT)	-76% 1.76 [0.46-6.82]	death 5/34	3/36
Mulhem	-86% 1.86 [0.21-5.24]	death 1/8	515/3,211
Aghajani	19% 0.81 [0.46-1.46]	death 46 (n)	945 (n)
Elhadi (ICU)	-11% 1.11 [0.81-1.51]	death 14/21	267/444
Pourhoseingholi	-2% 1.02 [0.72-1.44]	death 42/123	297/2,345
Arch (PSM)	20% 0.80 [0.64-0.98]	death 203/1,491	777/4,676
Barrat-Due (DB RCT)	0% 1.00 [0.20-4.60]	death 3/42	4/57
Ohl (PSM)	-6% 1.06 [0.83-1.36]	death 143/1,172	124/1,172
Madan	44% 0.56 [0.33-0.95]	death 23/398	27/260
Kuno (PSM)	1% 0.99 [0.84-1.17]	death 214/999	216/999
Diaz	35% 0.65 [0.46-0.92]	death 33/286	173/852
Ader (RCT)	6% 0.94 [0.59-1.45]	death 34/414	37/418
Mozaffari	12% 0.88 [0.81-0.96]	death 4,441/28,855	5,499/28,855
Schmidt (PSM)	-509% 6.09 [2.71-13.7]	severe case 43 (n)	434 (n)
Jamir (ICU)	8% 0.92 [0.55-1.55]	death 60/181	41/85
Mustafa	33% 0.67 [0.38-1.20]	death 16/200	29/244
Ali (RCT)	12% 0.88 [0.72-1.07]	death 127/634	152/647
Kurniyanto	-460% 5.60 [2.32-13.5]	death 7/45	12/432
Siraj	53% 0.47 [0.35-0.62]	death 108/413	197/587
Salehi (ICU)	37% 0.63 [0.43-0.94]	death 17/40	57/85
Elec	19% 0.81 [0.38-1.69]	death 7/38	29/127
Zangeneh (ICU)	32% 0.68 [0.45-1.01]	death n/a	n/a
Malundo	-17% 1.17 [0.80-1.70]	death 24/115	197/1,100
Bowen	-57% 1.57 [1.25-1.97]	death 817 (n)	3,814 (n)
Raad	42% 0.58 [0.39-0.88]	death n/a	n/a
Oku	-40% 1.40 [0.41-4.36]	death 3/46	8/172
Behboodikhah	38% 0.62 [0.30-1.30]	death 1,214 (n)	960 (n)
Hartantri	11% 0.89 [0.31-2.53]	death n/a	n/a
Alshamrani (PSM)	17% 0.83 [0.72-0.93]	death 137/246	725/1,078
Mitsushima	-44% 1.44 [1.09-1.90]	death n/a	n/a
Punzalan	-42% 1.42 [0.92-2.20]	death 47/224	26/176
Kim	-1612% 17.12 [0.19-1565]	death 14/145	0/22
Aweimer	-13% 1.13 [0.93-1.37]	death 40/51	68/98
Arfijanto	1% 0.99 [0.64-1.53]	viral+ 17/44	46/118
Bavaro (PSW)	7% 0.93 [0.89-0.97]	severe case 120 (n)	211 (n)
Shamsi	-23% 1.23 [0.56-2.69]	death 8/53	16/130
Mozaffari (PSM)	25% 0.75 [0.68-0.83]	death 14,169 (n)	5,341 (n)
Nadeem	-12% 1.12 [0.39-3.26]	death 12/96	4/36
Burhan (ICU)	-15% 1.15 [0.96-1.37]	death 33/43	345/516
Hagman	0% 1.00 [0.60-1.80]	death 105 (n)	213 (n)
Ho	-62% 1.62 [1.35-1.95]	death 5,294 (n)	21,151 (n)
Amirizadeh (ICU)	-3% 1.03 [0.86-1.24]	death 31/35	30/35
Muntean	-45% 1.45 [1.04-2.03]	death 71/287	45/264
Chang	-185% 2.85 [1.03-7.85]	death 81 (n)	81 (n)






### Efficacy in COVID-19 remdesivir studies (pooled effects)

c19early.org


March 2024



### Efficacy in COVID-19 studies (pooled effects)

c19early.org


March 2024



### Timeline of COVID-19 remdesivir studies (pooled effects)

c19early.org

March 2024



**Figure 1. A. Random effects meta-analysis.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes, and the heterogeneity section for discussion. Effect extraction is pre-specified, using the most serious outcome reported. For details of effect extraction see the appendix. **B. Scatter plot showing the most serious outcome in all studies,**

and for studies within each stage. Diamonds shows the results of random effects meta-analysis. **C. Results within the context of multiple COVID-19 treatments.** 0.6% of 6,686 proposed treatments show efficacy [c19early.org](#). **D. Timeline of results in remdesivir studies.**


## Introduction

**Immediate treatment recommended.** SARS-CoV-2 infection primarily begins in the upper respiratory tract and may progress to the lower respiratory tract, other tissues, and the nervous and cardiovascular systems, which may lead to cytokine storm, pneumonia, ARDS, neurological issues [Scardua-Silva, Yang](#), cardiovascular complications [Eberhardt](#), organ failure, and death. Minimizing replication as early as possible is recommended.

**Many treatments are expected to modulate infection.** SARS-CoV-2 infection and replication involves the complex interplay of 50+ host and viral proteins and other factors [Note A, Malone, Murigneux, Lv, Lui](#), providing many therapeutic targets for which many existing compounds have known activity. Scientists have predicted that over 6,000 compounds may reduce COVID-19 risk [c19early.org](#) [\(B\)](#), either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications.

**Analysis.** We analyze all significant controlled studies of remdesivir for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random effects meta-analysis results for all studies, studies within each treatment stage, individual outcomes, peer-reviewed studies, Randomized Controlled Trials (RCTs), and higher quality studies.

**Treatment timing.** Figure 2 shows stages of possible treatment for COVID-19. Prophylaxis refers to regularly taking medication before becoming sick, in order to prevent or minimize infection. Early Treatment refers to treatment immediately or soon after symptoms appear, while Late Treatment refers to more delayed treatment.



**Figure 2.** Treatment stages.

## Preclinical Research

4 *In Vitro* studies support the efficacy of remdesivir [De Forni, Delandre, Jeffreys, Mohd Abd Razak](#).

An *In Vivo* animal study supports the efficacy of remdesivir [Vermillion](#).

[Vermillion](#) investigate a novel formulation of remdesivir that may be more effective for COVID-19.

Preclinical research is an important part of the development of treatments, however results may be very different in clinical trials. Preclinical results are not used in this paper.

## Results

Table 1 summarizes the results for all stages combined, for Randomized Controlled Trials, for peer-reviewed studies, after exclusions, and for specific outcomes. Table 2 shows results by treatment stage. Figure 3, 4, 5, 6, 7, 8, 9, 10, and 11 show forest plots for random effects meta-analysis of all studies with pooled effects, mortality results, ventilation, ICU admission, hospitalization, progression, recovery, viral clearance, and peer reviewed studies.

	<i>Improvement</i>	<i>Studies</i>	<i>Patients</i>	<i>Authors</i>
All studies	<b>6%</b> [-1-12%]	68	184,656	1,035
After exclusions	<b>7%</b> [-1-13%]	49	163,724	821
Peer-reviewed studies	<b>3%</b> [-5-10%]	61	174,632	919
Randomized Controlled Trials	<b>12%</b> [-2-23%]	10	10,313	321
Mortality	<b>7%</b> [-1-14%]	58	182,432	840
Ventilation	<b>-13%</b> [-55-17%]	9	33,952	158
ICU admission	<b>-30%</b> [-51--12%] ***	4	3,473	23
Hospitalization	<b>-8%</b> [-33-12%]	9	6,049	200
Recovery	<b>21%</b> [12-29%] ****	5	2,502	148
Viral	<b>10%</b> [-14-29%]	5	776	78
RCT mortality	<b>9%</b> [-1-18%]	8	9,615	249
RCT hospitalization	<b>42%</b> [-87-82%]	3	1,979	157

**Table 1.** Random effects meta-analysis for all stages combined, for Randomized Controlled Trials, for peer-reviewed studies, after exclusions, and for specific outcomes. Results show the percentage improvement with treatment and the 95% confidence interval. \*  $p<0.05$  \*\*  $p<0.01$  \*\*\*  $p<0.001$ .

	<i>Early treatment</i>	<i>Late treatment</i>
All studies	35% [-29-67%]	5% [-1-12%]
After exclusions	33% [-57-71%]	6% [-1-13%]
Peer-reviewed studies	24% [-67-65%]	2% [-5-10%]
Randomized Controlled Trials	85% [42-96%] **	9% [-1-18%]
Mortality	66% [9-87%] *	7% [-1-14%]
Ventilation		-13% [-55-17%]
ICU admission		-30% [-51--12%] ***
Hospitalization	34% [-57-72%]	-14% [-39-6%]
Recovery	27% [9-42%] **	18% [5-29%] **
Viral	-1% [-122-54%]	4% [-11-17%]
RCT mortality		9% [-1-18%]
RCT hospitalization	71% [27-89%] **	-11% [-23-1%] *

**Table 2.** Random effects meta-analysis results by treatment stage.

Results show the percentage improvement with treatment, the 95% confidence interval, and the number of studies for the stage. \*  $p < 0.05$

\*\*  $p < 0.01$  \*\*\*  $p < 0.001$ .

# Remdesivir COVID-19 studies

c19early.org


March 2024

	Improvement, RR [CI]	Treatment	Control
Madan (ES)	66% 0.34 [0.12-0.96]	death 4/112	27/260
Gottlieb (DB RCT)	87% 0.13 [0.03-0.59]	death/hosp. 2/279	15/283
Piccicaccho	66% 0.34 [0.01-8.32]	death 0/82	1/90
Kneidinger	20% 0.80 [0.35-1.82]	severe case 6/46	28/172
Ong	-75% 1.75 [0.23-13.0]	recov. time 4 (n)	14 (n)
Chew	-68% 1.68 [0.51-5.58]	progression 12 (n)	151 (n)
Jittamala (RCT)	66% 0.34 [0.01-8.12]	hosp. 0/67	1/69
Seah	-129% 2.29 [0.26-20.1]	no recov. 2/7	1/8


**Early treatment 35%** 0.65 [0.33-1.29] 14/609 73/1,047

Tau<sup>2</sup> = 0.34, I<sup>2</sup> = 38.5%, p = 0.22

	Improvement, RR [CI]	Treatment	Control
Wang (RCT)	-9% 1.09 [0.54-2.18]	death 22/158	10/78
Olender	59% 0.41 [0.24-0.71]	death 24/312	102/818
Spinner (RCT)	35% 0.65 [0.18-2.40]	death 5/384	4/200
Pasquini (ICU)	16% 0.84 [0.69-0.94]	death 14/25	24/26
Fried	61% 0.39 [0.15-0.99]	death 4/48	2,510/11,673
Beigel (RCT)	27% 0.73 [0.52-1.03]	death 541 (n)	521 (n)
SOLIDARITY .. (RCT)	5% 0.95 [0.81-1.11]	death 301/2,743	303/2,708
El-Solh	29% 0.71 [0.52-0.97]	death 63/219	202/424
Flisiak	49% 0.51 [0.19-1.30]	death 5/122	17/211
Garibaldi	20% 0.80 [0.46-1.41]	death 23/303	45/303
Ullah	-100% 2.00 [0.67-5.94]	death 8/30	4/30
Yeramaneni	-24% 1.24 [0.11-14.2]	death 32 (n)	7,126 (n)
Goldberg	9% 0.91 [0.50-1.67]	hosp. time 29 (n)	113 (n)
Tsuzuki	-4% 1.04 [0.98-1.09]	death 69/824	285/11,663
Mahajan (RCT)	-76% 1.76 [0.46-6.82]	death 5/34	3/36
Mulhem	-86% 1.86 [0.21-5.24]	death 1/8	515/3,211
Aghajani	19% 0.81 [0.46-1.46]	death 46 (n)	945 (n)
Elhadi (ICU)	-11% 1.11 [0.81-1.51]	death 14/21	267/444
Pourhoseingholi	-2% 1.02 [0.72-1.44]	death 42/123	297/2,345
Arch (PSM)	20% 0.80 [0.64-0.98]	death 203/1,491	777/4,676
Barrat-Due (DB RCT)	0% 1.00 [0.20-4.60]	death 3/42	4/57
Ohl (PSM)	-6% 1.06 [0.83-1.36]	death 143/1,172	124/1,172
Madan	44% 0.56 [0.33-0.95]	death 23/398	27/260
Kuno (PSM)	1% 0.99 [0.84-1.17]	death 214/999	216/999
Diaz	35% 0.65 [0.46-0.92]	death 33/286	173/852
Ader (RCT)	6% 0.94 [0.59-1.45]	death 34/414	37/418
Mozaffari	12% 0.88 [0.81-0.96]	death 4,441/28,855	5,499/28,855
Schmidt (PSM)	-509% 6.09 [2.71-13.7]	severe case 43 (n)	434 (n)
Jamir (ICU)	8% 0.92 [0.55-1.55]	death 60/181	41/85
Mustafa	33% 0.67 [0.38-1.20]	death 16/200	29/244
Ali (RCT)	12% 0.88 [0.72-1.07]	death 127/634	152/647
Kurniyanto	-460% 5.60 [2.32-13.5]	death 7/45	12/432
Siraj	53% 0.47 [0.35-0.62]	death 108/413	197/587
Salehi (ICU)	37% 0.63 [0.43-0.94]	death 17/40	57/85
Elec	19% 0.81 [0.38-1.69]	death 7/38	29/127
Zangeneh (ICU)	32% 0.68 [0.45-1.01]	death n/a	n/a
Malundo	-17% 1.17 [0.80-1.70]	death 24/115	197/1,100
Bowen	-57% 1.57 [1.25-1.97]	death 817 (n)	3,814 (n)
Raad	42% 0.58 [0.39-0.88]	death n/a	n/a
Oku	-40% 1.40 [0.41-4.36]	death 3/46	8/172
Behboodikhah	38% 0.62 [0.30-1.30]	death 1,214 (n)	960 (n)
Hartantri	11% 0.89 [0.31-2.53]	death n/a	n/a
Alshamrani (PSM)	17% 0.83 [0.72-0.93]	death 137/246	725/1,078
Mitsushima	-44% 1.44 [1.09-1.90]	death n/a	n/a
Punzalan	-42% 1.42 [0.92-2.20]	death 47/224	26/176
Kim	-1612% 17.12 [0.19-1565]	death 14/145	0/22
Aweimer	-13% 1.13 [0.93-1.37]	death 40/51	68/98
Arfijanto	1% 0.99 [0.64-1.53]	viral+ 17/44	46/118
Bavaro (PSW)	7% 0.93 [0.89-0.97]	severe case 120 (n)	211 (n)
Shamsi	-23% 1.23 [0.56-2.69]	death 8/53	16/130
Mozaffari (PSM)	25% 0.75 [0.68-0.83]	death 14,169 (n)	5,341 (n)
Nadeem	-12% 1.12 [0.39-3.26]	death 12/96	4/36
Burhan (ICU)	-15% 1.15 [0.96-1.37]	death 33/43	345/516
Hagman	0% 1.00 [0.60-1.80]	death 105 (n)	213 (n)
Ho	-62% 1.62 [1.35-1.95]	death 5,294 (n)	21,151 (n)
Amirizadeh (ICU)	-3% 1.03 [0.86-1.24]	death 31/35	30/35
Muntean	-45% 1.45 [1.04-2.03]	death 71/287	45/264
Chang	-185% 2.85 [1.03-7.85]	death 81 (n)	81 (n)







**Figure 3. Random effects meta-analysis for all studies with pooled effects.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes, and the heterogeneity section for discussion. Effect extraction is pre-specified, using the most serious outcome reported. For details of effect extraction see the appendix.

# 58 remdesivir COVID-19 mortality results

c19early.org

March 2024

	Improvement, RR [CI]	Treatment	Control
Madan (ES)	66% 0.34 [0.12-0.96]	4/112	27/260
Piccicacco	66% 0.34 [0.01-8.32]	0/82	1/90

**Early treatment** 66% 0.34 [0.13-0.91] 4/194 28/350


Tau<sup>2</sup> = 0.00, I<sup>2</sup> = 0.0%, p = 0.032

	Improvement, RR [CI]	Treatment	Control
Wang (RCT)	-9% 1.09 [0.54-2.18]	22/158	10/78
Olender	59% 0.41 [0.24-0.71]	24/312	102/818
Spinner (RCT)	35% 0.65 [0.18-2.40]	5/384	4/200
Pasquini (ICU)	16% 0.84 [0.69-0.94]	14/25	24/26
Fried	61% 0.39 [0.15-0.99]	4/48	2,510/11,673
Beigel (RCT)	27% 0.73 [0.52-1.03]	541 (n)	521 (n)
SOLIDARITY .. (RCT)	5% 0.95 [0.81-1.11]	301/2,743	303/2,708
El-Solh	29% 0.71 [0.52-0.97]	63/219	202/424
Flisiak	49% 0.51 [0.19-1.30]	5/122	17/211
Garibaldi	20% 0.80 [0.46-1.41]	23/303	45/303
Ullah	-100% 2.00 [0.67-5.94]	8/30	4/30
Yeramaneni	-24% 1.24 [0.11-14.2]	32 (n)	7,126 (n)
Tsuzuki	-4% 1.04 [0.98-1.09]	69/824	285/11,663
Mahajan (RCT)	-76% 1.76 [0.46-6.82]	5/34	3/36
Mulhem	-86% 1.86 [0.21-5.24]	1/8	515/3,211
Aghajani	19% 0.81 [0.46-1.46]	46 (n)	945 (n)
Elhadi (ICU)	-11% 1.11 [0.81-1.51]	14/21	267/444
Pourhoseingholi	-2% 1.02 [0.72-1.44]	42/123	297/2,345
Arch (PSM)	20% 0.80 [0.64-0.98]	203/1,491	777/4,676
Barrat-Due (DB RCT)	0% 1.00 [0.20-4.60]	3/42	4/57
Ohl (PSM)	-6% 1.06 [0.83-1.36]	143/1,172	124/1,172
Madan	44% 0.56 [0.33-0.95]	23/398	27/260
Kuno (PSM)	1% 0.99 [0.84-1.17]	214/999	216/999
Diaz	35% 0.65 [0.46-0.92]	33/286	173/852
Ader (RCT)	6% 0.94 [0.59-1.45]	34/414	37/418
Mozaffari	12% 0.88 [0.81-0.96]	4,441/28,855	5,499/28,855
Jamir (ICU)	8% 0.92 [0.55-1.55]	60/181	41/85
Mustafa	33% 0.67 [0.38-1.20]	16/200	29/244
Ali (RCT)	12% 0.88 [0.72-1.07]	127/634	152/647
Kurniyanto	-460% 5.60 [2.32-13.5]	7/45	12/432
Siraj	53% 0.47 [0.35-0.62]	108/413	197/587
Salehi (ICU)	37% 0.63 [0.43-0.94]	17/40	57/85
Elec	19% 0.81 [0.38-1.69]	7/38	29/127
Zangeneh (ICU)	32% 0.68 [0.45-1.01]	n/a	n/a
Malundo	-17% 1.17 [0.80-1.70]	24/115	197/1,100
Bowen	-57% 1.57 [1.25-1.97]	817 (n)	3,814 (n)
Raad	42% 0.58 [0.39-0.88]	n/a	n/a
Oku	-40% 1.40 [0.41-4.36]	3/46	8/172
Behboodikhah	38% 0.62 [0.30-1.30]	1,214 (n)	960 (n)
Hartantri	11% 0.89 [0.31-2.53]	n/a	n/a
Alshamrani (PSM)	17% 0.83 [0.72-0.93]	137/246	725/1,078
Mitsushima	-44% 1.44 [1.09-1.90]	n/a	n/a
Punzalan	-42% 1.42 [0.92-2.20]	47/224	26/176
Kim	-1612% 17.12 [0.19-1565]	14/145	0/22
Aweimer	-13% 1.13 [0.93-1.37]	40/51	68/98
Shamsi	-23% 1.23 [0.56-2.69]	8/53	16/130
Mozaffari (PSM)	25% 0.75 [0.68-0.83]	14,169 (n)	5,341 (n)
Nadeem	-12% 1.12 [0.39-3.26]	12/96	4/36
Burhan (ICU)	-15% 1.15 [0.96-1.37]	33/43	345/516
Hagman	0% 1.00 [0.60-1.80]	105 (n)	213 (n)
Ho	-62% 1.62 [1.35-1.95]	5,294 (n)	21,151 (n)
Amirizadeh (ICU)	-3% 1.03 [0.86-1.24]	31/35	30/35
Muntean	-45% 1.45 [1.04-2.03]	71/287	45/264
Chang	-185% 2.85 [1.03-7.85]	81 (n)	81 (n)
Liao	-25% 1.25 [0.55-2.86]	37/59	3/6
Sokolski	0% 1.00 [0.67-1.47]	88 (n)	460 (n)

**Late treatment** 7% 0.93 [0.86-1.01] 6,493/64,349 13,429/117,911

Tau<sup>2</sup> = 0.05, I<sup>2</sup> = 77.4%, p = 0.098

**All studies** 7% 0.93 [0.86-1.01] 6,497/64,543 13,457/118,261




$\text{Tau}^2 = 0.05$ ,  $I^2 = 77.0\%$ ,  $p = 0.094$

Favors remdesivir      Favors control


**Figure 4.** Random effects meta-analysis for mortality results.

## 9 remdesivir COVID-19 mechanical ventilation results



**Figure 5.** Random effects meta-analysis for ventilation.

## 4 remdesivir COVID-19 ICU results



**Figure 6.** Random effects meta-analysis for ICU admission.

## 9 remdesivir COVID-19 hospitalization results

c19early.org  
March 2024




Figure 7. Random effects meta-analysis for hospitalization.

## 6 remdesivir COVID-19 progression results

c19early.org  
March 2024





Figure 8. Random effects meta-analysis for progression.

## 5 remdesivir COVID-19 recovery results


c19early.org  
March 2024



**Figure 9.** Random effects meta-analysis for recovery.

## 5 remdesivir COVID-19 viral clearance results

c19early.org  
March 2024



**Figure 10.** Random effects meta-analysis for viral clearance.

# 61 remdesivir COVID-19 peer reviewed studies

c19early.org

March 2024

	Improvement, RR [CI]	Treatment	Control
Gottlieb (DB RCT)	87% 0.13 [0.03-0.59]	death/hosp.	2/279 15/283
Piccicaccho	66% 0.34 [0.01-8.32]	death	0/82 1/90
Kneidinger	20% 0.80 [0.35-1.82]	severe case	6/46 28/172
Ong	-75% 1.75 [0.23-13.0]	recov. time	4 (n) 14 (n)
Chew	-68% 1.68 [0.51-5.58]	progression	12 (n) 151 (n)
Jittamala (RCT)	66% 0.34 [0.01-8.12]	hosp.	0/67 1/69
Seah	-129% 2.29 [0.26-20.1]	no recov.	2/7 1/8

**Early treatment 24%** 0.76 [0.35-1.67] 10/497 46/787

Tau<sup>2</sup> = 0.37, I<sup>2</sup> = 36.5%, p = 0.51

	Improvement, RR [CI]	Treatment	Control
Wang (RCT)	-9% 1.09 [0.54-2.18]	death	22/158 10/78
Olender	59% 0.41 [0.24-0.71]	death	24/312 102/818
Spinner (RCT)	35% 0.65 [0.18-2.40]	death	5/384 4/200
Pasquini (ICU)	16% 0.84 [0.69-0.94]	death	14/25 24/26
Fried	61% 0.39 [0.15-0.99]	death	4/48 2,510/11,673
Beigel (RCT)	27% 0.73 [0.52-1.03]	death	541 (n) 521 (n)
SOLIDARITY .. (RCT)	5% 0.95 [0.81-1.11]	death	301/2,743 303/2,708
El-Solh	29% 0.71 [0.52-0.97]	death	63/219 202/424
Flisiak	49% 0.51 [0.19-1.30]	death	5/122 17/211
Ullah	-100% 2.00 [0.67-5.94]	death	8/30 4/30
Yeramaneni	-24% 1.24 [0.11-14.2]	death	32 (n) 7,126 (n)
Goldberg	9% 0.91 [0.50-1.67]	hosp. time	29 (n) 113 (n)
Tsuzuki	-4% 1.04 [0.98-1.09]	death	69/824 285/11,663
Mahajan (RCT)	-76% 1.76 [0.46-6.82]	death	5/34 3/36
Mulhem	-86% 1.86 [0.21-5.24]	death	1/8 515/3,211
Aghajani	19% 0.81 [0.46-1.46]	death	46 (n) 945 (n)
Elhadi (ICU)	-11% 1.11 [0.81-1.51]	death	14/21 267/444
Barrat-Due (DB RCT)	0% 1.00 [0.20-4.60]	death	3/42 4/57
Ohi (PSM)	-6% 1.06 [0.83-1.36]	death	143/1,172 124/1,172
Kuno (PSM)	1% 0.99 [0.84-1.17]	death	214/999 216/999
Diaz	35% 0.65 [0.46-0.92]	death	33/286 173/852
Ader (RCT)	6% 0.94 [0.59-1.45]	death	34/414 37/418
Mozaffari	12% 0.88 [0.81-0.96]	death	4,441/28,855 5,499/28,855
Schmidt (PSM)	-509% 6.09 [2.71-13.7]	severe case	43 (n) 434 (n)
Jamir (ICU)	8% 0.92 [0.55-1.55]	death	60/181 41/85
Mustafa	33% 0.67 [0.38-1.20]	death	16/200 29/244
Ali (RCT)	12% 0.88 [0.72-1.07]	death	127/634 152/647
Kurniyanto	-460% 5.60 [2.32-13.5]	death	7/45 12/432
Siraj	53% 0.47 [0.35-0.62]	death	108/413 197/587
Elec	19% 0.81 [0.38-1.69]	death	7/38 29/127
Zangeneh (ICU)	32% 0.68 [0.45-1.01]	death	n/a n/a
Malundo	-17% 1.17 [0.80-1.70]	death	24/115 197/1,100
Bowen	-57% 1.57 [1.25-1.97]	death	817 (n) 3,814 (n)
Oku	-40% 1.40 [0.41-4.36]	death	3/46 8/172
Behboodikhah	38% 0.62 [0.30-1.30]	death	1,214 (n) 960 (n)
Hartantri	11% 0.89 [0.31-2.53]	death	n/a n/a
Alshamrani (PSM)	17% 0.83 [0.72-0.93]	death	137/246 725/1,078
Mitsushima	-44% 1.44 [1.09-1.90]	death	n/a n/a
Punzalan	-42% 1.42 [0.92-2.20]	death	47/224 26/176
Kim	-1612% 17.12 [0.19-1565]	death	14/145 0/22
Aweimer	-13% 1.13 [0.93-1.37]	death	40/51 68/98
Arfijanto	1% 0.99 [0.64-1.53]	viral+	17/44 46/118
Bavaro (PSW)	7% 0.93 [0.89-0.97]	severe case	120 (n) 211 (n)
Shamsi	-23% 1.23 [0.56-2.69]	death	8/53 16/130
Mozaffari (PSM)	25% 0.75 [0.68-0.83]	death	14,169 (n) 5,341 (n)
Nadeem	-12% 1.12 [0.39-3.26]	death	12/96 4/36
Burhan (ICU)	-15% 1.15 [0.96-1.37]	death	33/43 345/516
Hagman	0% 1.00 [0.60-1.80]	death	105 (n) 213 (n)
Ho	-62% 1.62 [1.35-1.95]	death	5,294 (n) 21,151 (n)
Amirizadeh (ICU)	-3% 1.03 [0.86-1.24]	death	31/35 30/35
Muntean	-45% 1.45 [1.04-2.03]	death	71/287 45/264
Chang	-185% 2.85 [1.03-7.85]	death	81 (n) 81 (n)
Liao	-25% 1.25 [0.55-2.86]	death	37/59 3/6
Sokolski	0% 1.00 [0.67-1.47]	death	88 (n) 460 (n)


**Late treatment 2%** 0.98 [0.90-1.05] 6,202/62,230 12,272/111,118


Tau<sup>2</sup> = 0.04, I<sup>2</sup> = 78.9%, p = 0.53

**All studies 20%** 0.97 [0.90-1.05]

6 212/62 777

12 318/111 905





**Figure 11. Random effects meta-analysis for peer reviewed studies.** Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. *Zeraatkar et al.* analyze 356 COVID-19 trials, finding no significant evidence that preprint results are inconsistent with peer-reviewed studies. They also show extremely long peer-review delays, with a median of 6 months to journal publication. A six month delay was equivalent to around 1.5 million deaths during the first two years of the pandemic. Authors recommend using preprint evidence, with appropriate checks for potential falsified data, which provides higher certainty much earlier. *Davidson et al.* also showed no important difference between meta-analysis results of preprints and peer-reviewed publications for COVID-19, based on 37 meta analyses including 114 trials.

## Randomized Controlled Trials (RCTs)

Figure 12 shows a comparison of results for RCTs and non-RCT studies. The median effect size for RCTs is 9% improvement, compared to 0% for other studies. Figure 13, 14, and 15 show forest plots for random effects meta-analysis of all Randomized Controlled Trials, RCT mortality results, and RCT hospitalization results. RCT results are included in Table 1 and Table 2.

**RCTs have many potential biases.** Bias in clinical research may be defined as something that tends to make conclusions differ systematically from the truth. RCTs help to make study groups more similar and can provide a higher level of evidence, however they are subject to many biases *Jadad*, and analysis of double-blind RCTs has identified extreme levels of bias *Gotzsche*. For COVID-19, the overhead may delay treatment, dramatically compromising efficacy; they may encourage monotherapy for simplicity at the cost of efficacy which may rely on combined or synergistic effects; the participants that sign up may not reflect real world usage or the population that benefits most in terms of age, comorbidities, severity of illness, or other factors; standard of care may be compromised and unable to evolve quickly based on emerging research for new diseases; errors may be made in randomization and medication delivery; and investigators may have hidden agendas or vested interests influencing design, operation, analysis, and the potential for fraud. All of these biases have been observed with COVID-19 RCTs. There is no guarantee that a specific RCT provides a higher level of evidence.


**Conflicts of interest for COVID-19 RCTs.** RCTs are expensive and many RCTs are funded by pharmaceutical companies or interests closely aligned with pharmaceutical companies. For COVID-19, this creates an incentive to show efficacy for patented commercial products, and an incentive to show a lack of efficacy for inexpensive treatments. The bias is expected to be significant, for example *Als-Nielsen et al.* analyzed 370 RCTs from Cochrane reviews, showing that trials funded by for-profit organizations were 5 times more likely to recommend the experimental drug compared with those funded by nonprofit organizations. For COVID-19, some major philanthropic organizations are largely funded by investments with extreme conflicts of interest for and against specific COVID-19 interventions.

**RCTs for novel acute diseases requiring rapid treatment.** High quality RCTs for novel acute diseases are more challenging, with increased ethical issues due to the urgency of treatment, increased risk due to enrollment delays, and more difficult design with a rapidly evolving evidence base. For COVID-19, the most common site of initial infection is the upper respiratory tract. Immediate treatment is likely to be most successful and may prevent or slow progression to other parts of the body. For a non-prophylaxis RCT, it makes sense to provide treatment in advance and instruct patients to use it immediately on symptoms, just as some governments have done by providing medication kits in advance. Unfortunately, no RCTs have been done in this way. Every treatment RCT to date involves delayed treatment. Among the 66 treatments we have analyzed, 63% of RCTs involve very late treatment 5+ days after onset. No non-prophylaxis COVID-19 RCTs match the potential real-world use of early treatments (they may more accurately represent results for treatments that require visiting a medical facility, e.g., those requiring intravenous administration).

**Non-RCT studies have been shown to be reliable.** Evidence shows that non-RCT trials can also provide reliable results. *Concato et al.* found that well-designed observational studies do not systematically overestimate the magnitude of the effects of treatment compared to RCTs. *Anglemyer et al.* summarized reviews comparing RCTs to observational studies and found little evidence for significant differences in effect estimates. *Lee et al.* showed that only 14% of the guidelines of the Infectious Diseases Society of America were based on RCTs. Evaluation of studies relies on an understanding of the study and potential biases. Limitations in an RCT can outweigh the benefits, for example excessive dosages, excessive treatment delays, or Internet survey bias could have a greater effect on results. Ethical issues may also prevent running RCTs for known effective treatments. For more on issues with RCTs see *Deaton, Nichol*.

**Using all studies identifies efficacy 5.7+ months faster for COVID-19.** Currently, 44 of the treatments we analyze show statistically significant efficacy or harm, defined as  $\geq 10\%$  decreased risk or  $>0\%$  increased risk from  $\geq 3$  studies. Of the 44 treatments with statistically significant efficacy/harm, 28 have been confirmed in RCTs, with a mean delay of 5.7 months. When considering only low cost treatments, 23 have been confirmed with a delay of 6.9 months. For the 16 unconfirmed treatments, 3 have zero RCTs to date. The point estimates for the remaining 13 are all consistent with the overall results (benefit or harm), with 10 showing  $>20\%$ . The only treatments showing  $>10\%$  efficacy for all studies, but  $<10\%$  for RCTs are sotrovimab and aspirin.

**Summary.** We need to evaluate each trial on its own merits. RCTs for a given medication and disease may be more reliable, however they may also be less reliable. For off-patent medications, very high conflict of interest trials may be more likely to be RCTs, and more likely to be large trials that dominate meta analyses.




**Figure 12.** Results for RCTs and non-RCT studies.



## 10 remdesivir COVID-19 Randomized Controlled Trials

c19early.org

March 2024




**Figure 13.** Random effects meta-analysis for all Randomized Controlled Trials. This plot shows pooled effects, see the specific outcome analyses for individual outcomes, and the heterogeneity section for discussion. Effect extraction is pre-specified, using the most serious outcome reported. For details of effect extraction see the appendix.

## 8 remdesivir COVID-19 RCT mortality results

c19early.org


March 2024



**Figure 14.** Random effects meta-analysis for RCT mortality results.

### 3 remdesivir COVID-19 RCT hospitalization results

c19early.org  
March 2024



**Figure 15.** Random effects meta-analysis for RCT hospitalization results.

## Exclusions

To avoid bias in the selection of studies, we analyze all non-retracted studies. Here we show the results after excluding studies with major issues likely to alter results, non-standard studies, and studies where very minimal detail is currently available. Our bias evaluation is based on analysis of each study and identifying when there is a significant chance that limitations will substantially change the outcome of the study. We believe this can be more valuable than checklist-based approaches such as Cochrane GRADE, which may underemphasize serious issues not captured in the checklists, overemphasize issues unlikely to alter outcomes in specific cases (for example, lack of blinding for an objective mortality outcome, or certain specifics of randomization with a very large effect size), and can be easily influenced by potential bias.

The studies excluded are as below. Figure 16 shows a forest plot for random effects meta-analysis of all studies after exclusions.

*Arfijanto*, unadjusted results with no group details.

*El-Solh*, very late stage, >50% on oxygen/ventilation at baseline; substantial unadjusted confounding by indication likely; significant confounding by contraindications possible.

*Elec*, substantial confounding by time possible due to significant changes in SOC and treatment propensity during the study period.

*Elhadi*, unadjusted results with no group details.

*Fried*, excessive unadjusted differences between groups; substantial unadjusted confounding by indication likely.

*Kurniyanto*, unadjusted results with no group details; substantial unadjusted confounding by indication likely.

*Liao*, unadjusted results with no group details.

*Madan*, unadjusted results with no group details.

*Madan (B)*, excessive unadjusted differences between groups.

*Malundo*, unadjusted results with no group details.

*Mulhem*, substantial unadjusted confounding by indication likely; substantial confounding by time possible due to significant changes in SOC and treatment propensity during the study period.

*Mustafa*, unadjusted results with no group details.

*Nadeem*, unadjusted results with no group details.

*Oku*, unadjusted results with no group details.

*Salehi*, unadjusted results with no group details.

*Schmidt*, confounding by indication is likely and adjustments do not consider COVID-19 severity at baseline.

*Seah*, unadjusted results with significant baseline differences.

*Shamsi*, unadjusted results with no group details.

*Sokolski*, unadjusted results with no group details.

# Remdesivir COVID-19 studies after exclusions

c19early.org

March 2024

	Improvement, RR [CI]	Treatment	Control
Gottlieb (DB RCT)	87% 0.13 [0.03-0.59]	death/hosp. 2/279	15/283
Piccicacchio	66% 0.34 [0.01-8.32]	death 0/82	1/90
Kneidinger	20% 0.80 [0.35-1.82]	severe case 6/46	28/172
Ong	-75% 1.75 [0.23-13.0]	recov. time 4 (n)	14 (n)
Chew	-68% 1.68 [0.51-5.58]	progression 12 (n)	151 (n)
Jittamala (RCT)	66% 0.34 [0.01-8.12]	hosp. 0/67	1/69

**Early treatment** 33% 0.67 [0.29-1.57] 8/490 45/779

Tau<sup>2</sup> = 0.42, I<sup>2</sup> = 40.9%, p = 0.36

	Improvement, RR [CI]	Treatment	Control
Wang (RCT)	-9% 1.09 [0.54-2.18]	death 22/158	10/78
Olender	59% 0.41 [0.24-0.71]	death 24/312	102/818
Spinner (RCT)	35% 0.65 [0.18-2.40]	death 5/384	4/200
Pasquini (ICU)	16% 0.84 [0.69-0.94]	death 14/25	24/26
Beigel (RCT)	27% 0.73 [0.52-1.03]	death 541 (n)	521 (n)
SOLIDARITY .. (RCT)	5% 0.95 [0.81-1.11]	death 301/2,743	303/2,708
Flisiak	49% 0.51 [0.19-1.30]	death 5/122	17/211
Garibaldi	20% 0.80 [0.46-1.41]	death 23/303	45/303
Ullah	-100% 2.00 [0.67-5.94]	death 8/30	4/30
Yeramaneni	-24% 1.24 [0.11-14.2]	death 32 (n)	7,126 (n)
Goldberg	9% 0.91 [0.50-1.67]	hosp. time 29 (n)	113 (n)
Tsuzuki	-4% 1.04 [0.98-1.09]	death 69/824	285/11,663
Mahajan (RCT)	-76% 1.76 [0.46-6.82]	death 5/34	3/36
Aghajani	19% 0.81 [0.46-1.46]	death 46 (n)	945 (n)
Pourhoseingholi	-2% 1.02 [0.72-1.44]	death 42/123	297/2,345
Arch (PSM)	20% 0.80 [0.64-0.98]	death 203/1,491	777/4,676
Barrat-Due (DB RCT)	0% 1.00 [0.20-4.60]	death 3/42	4/57
Ohl (PSM)	-6% 1.06 [0.83-1.36]	death 143/1,172	124/1,172
Kuno (PSM)	1% 0.99 [0.84-1.17]	death 214/999	216/999
Diaz	35% 0.65 [0.46-0.92]	death 33/286	173/852
Ader (RCT)	6% 0.94 [0.59-1.45]	death 34/414	37/418
Mozaffari	12% 0.88 [0.81-0.96]	death 4,441/28,855	5,499/28,855
Jamir (ICU)	8% 0.92 [0.55-1.55]	death 60/181	41/85
Ali (RCT)	12% 0.88 [0.72-1.07]	death 127/634	152/647
Siraj	53% 0.47 [0.35-0.62]	death 108/413	197/587
Zangeneh (ICU)	32% 0.68 [0.45-1.01]	death n/a	n/a
Bowen	-57% 1.57 [1.25-1.97]	death 817 (n)	3,814 (n)
Raad	42% 0.58 [0.39-0.88]	death n/a	n/a
Behboodikhah	38% 0.62 [0.30-1.30]	death 1,214 (n)	960 (n)
Hartantri	11% 0.89 [0.31-2.53]	death n/a	n/a
Alshamrani (PSM)	17% 0.83 [0.72-0.93]	death 137/246	725/1,078
Mitsushima	-44% 1.44 [1.09-1.90]	death n/a	n/a
Punzalan	-42% 1.42 [0.92-2.20]	death 47/224	26/176
Kim	-1612% 17.12 [0.19-1565]	death 14/145	0/22
Aweimer	-13% 1.13 [0.93-1.37]	death 40/51	68/98
Bavaro (PSW)	7% 0.93 [0.89-0.97]	severe case 120 (n)	211 (n)
Mozaffari (PSM)	25% 0.75 [0.68-0.83]	death 14,169 (n)	5,341 (n)
Burhan (ICU)	-15% 1.15 [0.96-1.37]	death 33/43	345/516
Hagman	0% 1.00 [0.60-1.80]	death 105 (n)	213 (n)
Ho	-62% 1.62 [1.35-1.95]	death 5,294 (n)	21,151 (n)
Amirizadeh (ICU)	-3% 1.03 [0.86-1.24]	death 31/35	30/35
Muntean	-45% 1.45 [1.04-2.03]	death 71/287	45/264
Chang	-185% 2.85 [1.03-7.85]	death 81 (n)	81 (n)


**Late treatment** 6% 0.94 [0.87-1.01] 6,257/63,024 9,553/99,431

Tau<sup>2</sup> = 0.03, I<sup>2</sup> = 79.8%, p = 0.088

**All studies** 7% 0.93 [0.87-1.01] 6,265/63,514 9,598/100,210

Tau<sup>2</sup> = 0.03, I<sup>2</sup> = 77.9%, p = 0.069

Effect extraction pre-specified  
(most serious outcome, see appendix)



**Figure 16. Random effects meta-analysis for all studies after exclusions.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes, and the heterogeneity section for discussion. Effect extraction is pre-specified, using the most serious outcome reported. For details of effect extraction see the appendix.

# Heterogeneity


Heterogeneity in COVID-19 studies arises from many factors including:

**Treatment delay.** The time between infection or the onset of symptoms and treatment may critically affect how well a treatment works. For example an antiviral may be very effective when used early but may not be effective in late stage disease, and may even be harmful. Oseltamivir, for example, is generally only considered effective for influenza when used within 0-36 or 0-48 hours *McLean, Treanor*. Baloxavir studies for influenza also show that treatment delay is critical — *Ikematsu* report an 86% reduction in cases for post-exposure prophylaxis, *Hayden* show a 33 hour reduction in the time to alleviation of symptoms for treatment within 24 hours and a reduction of 13 hours for treatment within 24-48 hours, and *Kumar* report only 2.5 hours improvement for inpatient treatment.

Treatment delay	Result
Post exposure prophylaxis	86% fewer cases <i>Ikematsu</i>
<24 hours	-33 hours symptoms <i>Hayden</i>
24-48 hours	-13 hours symptoms <i>Hayden</i>
Inpatients	-2.5 hours to improvement <i>Kumar</i>

**Table 3.** Studies of baloxavir for influenza show that early treatment is more effective.

Figure 17 shows a mixed-effects meta-regression for efficacy as a function of treatment delay in COVID-19 studies from 66 treatments, showing that efficacy declines rapidly with treatment delay. Early treatment is critical for COVID-19.



**Figure 17.** Early treatment is more effective. Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 66 treatments.

**Patient demographics.** Details of the patient population including age and comorbidities may critically affect how well a treatment works. For example, many COVID-19 studies with relatively young low-comorbidity patients show all patients recovering quickly with or without treatment. In such cases, there is little room for an effective treatment to improve results (as in *López-Medina*).

**Effect measured.** Efficacy may differ significantly depending on the effect measured, for example a treatment may be very effective at reducing mortality, but less effective at minimizing cases or hospitalization. Or a treatment may have no effect on viral clearance while still being effective at reducing mortality.

**Variants.** There are many different variants of SARS-CoV-2 and efficacy may depend critically on the distribution of variants encountered by the patients in a study. For example, the Gamma variant shows significantly different characteristics *Faria, Karita, Nonaka, Zavascki*. Different mechanisms of action may be more or less effective depending on variants, for example the viral entry process for the omicron variant has moved towards TMPRSS2-independent fusion, suggesting that TMPRSS2 inhibitors may be less effective *Peacock, Willett*.

**Regimen.** Effectiveness may depend strongly on the dosage and treatment regimen.

**Other treatments.** The use of other treatments may significantly affect outcomes, including anything from supplements, other medications, or other kinds of treatment such as prone positioning.


**Medication quality.** The quality of medications may vary significantly between manufacturers and production batches, which may significantly affect efficacy and safety. *Williams* analyze ivermectin from 11 different sources, showing highly variable antiparasitic efficacy across different manufacturers. *Xu* analyze a treatment from two different manufacturers, showing 9 different impurities, with significantly different concentrations for each manufacturer.

**Pooled outcome analysis.** We present both pooled analyses and specific outcome analyses. Notably, pooled analysis often results in earlier detection of efficacy as shown in Figure 18. For many COVID-19 treatments, a reduction in mortality logically follows from a reduction in hospitalization, which follows from a reduction in symptomatic cases, etc. An antiviral tested with a low-risk population may report zero mortality in both arms, however a reduction in severity and improved viral clearance may translate into lower mortality among a high-risk population, and including these results in pooled analysis allows faster detection of efficacy. Trials with high-risk patients may also be restricted due to ethical concerns for treatments that are known or expected to be effective.

Pooled analysis enables using more of the available information. While there is much more information available, for example dose-response relationships, the advantage of the method used here is simplicity and transparency. Note that pooled analysis could hide efficacy, for example a treatment that is beneficial for late stage patients but has no effect on viral replication or early stage disease could show no efficacy in pooled analysis if most studies only examine viral clearance. While we present pooled results, we also present individual outcome analyses, which may be more informative for specific use cases.

**Pooled outcomes identify efficacy faster.** Currently, 44 of the treatments we analyze show statistically significant efficacy or harm, defined as  $\geq 10\%$  decreased risk or  $> 0\%$  increased risk from  $\geq 3$  studies. 88% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 3.6 months. When restricting to RCTs only, 50% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 6.1 months.

## Time when COVID-19 studies showed efficacy




**Figure 18.** The time when studies showed that treatments were effective, defined as statistically significant improvement of  $\geq 10\%$  from  $\geq 3$  studies. Pooled results typically show efficacy earlier than specific outcome results. Results from all studies often shows efficacy much earlier than when restricting to RCTs. Results reflect conditions as used in trials to date, these depend on the population treated, treatment delay, and treatment regimen.

**Meta analysis.** The distribution of studies will alter the outcome of a meta analysis. Consider a simplified example where everything is equal except for the treatment delay, and effectiveness decreases to zero or below with increasing delay. If there are many studies using very late treatment, the outcome may be negative, even though early treatment is very effective. This may have a greater effect than pooling different outcomes such as mortality and hospitalization. For example a treatment may have 50% efficacy for mortality but only 40% for hospitalization when used within 48 hours. However efficacy could be 0% when used late.

All meta analyses combine heterogeneous studies, varying in population, variants, and potentially all factors above, and therefore may obscure efficacy by including studies where treatment is less effective. Generally, we expect the estimated effect size from meta analysis to be less than that for the optimal case. Looking at all studies is valuable for providing an overview of all research, important to avoid cherry-picking, and informative when a positive result is found despite combining less-optimal situations. However, the resulting estimate does not apply to specific cases such as early treatment in high-risk populations. While we present results for all studies, we also present treatment time and individual outcome analyses, which may be more informative for specific use cases.

## Efficacy decreases with longer followup

Figure 19 shows a mixed-effects meta-regression of efficacy as a function of followup duration, which shows decreasing efficacy with longer followup. This may reflect antiviral efficacy being offset by side effects of treatment.



**Figure 19.** Efficacy decreases with longer followup. Meta-regression showing mortality efficacy as a function of followup duration in COVID-19 remdesivir studies.


## Discussion

**Retrospective studies may overestimate efficacy.** *Wilcock et al.* show that COVID-19 prescription treatments have been preferentially used by patients at lower risk. Retrospective studies may overestimate efficacy, and data for accurate adjustment may not be available. For example, patients with greater knowledge of effective treatments may be more likely to access prescription treatments but result in confounding because they are also more likely to use known beneficial non-prescription treatments.

**Publication bias.** Publishing is often biased towards positive results. Trials with patented drugs may have a financial conflict of interest that results in positive studies being more likely to be published, or bias towards more positive results. For example with molnupiravir, trials with negative results remain unpublished to date (CTRI/2021/05/033864 and CTRI/2021/08/0354242).

One method to evaluate bias is to compare prospective vs. retrospective studies. Prospective studies are more likely to be published regardless of the result, while retrospective studies are more likely to exhibit bias. For example, researchers may perform preliminary analysis with minimal effort and the results may influence their decision to continue. Retrospective studies also provide more opportunities for the specifics of data extraction and adjustments to influence results.

Figure 20 shows a scatter plot of results for prospective and retrospective studies. 31% of retrospective studies report a statistically significant positive effect for one or more outcomes, compared to 36% of prospective studies, showing similar results. The median effect size for retrospective studies is 1% improvement, compared to 6% for prospective studies, showing similar results.




**Figure 20.** Prospective vs. retrospective studies. The diamonds show the results of random effects meta-analysis.

**Funnel plot analysis.** Funnel plots have traditionally been used for analyzing publication bias. This is invalid for COVID-19 acute treatment trials — the underlying assumptions are invalid, which we can demonstrate with a simple example. Consider a set of hypothetical perfect trials with no bias. Figure 21 plot A shows a funnel plot for a simulation of 80 perfect trials, with random group sizes, and each patient's outcome randomly sampled (10% control event probability,



and a 30% effect size for treatment). Analysis shows no asymmetry ( $p > 0.05$ ). In plot B, we add a single typical variation in COVID-19 treatment trials — treatment delay. Consider that efficacy varies from 90% for treatment within 24 hours, reducing to 10% when treatment is delayed 3 days. In plot B, each trial's treatment delay is randomly selected. Analysis now shows highly significant asymmetry,  $p < 0.0001$ , with six variants of Egger's test all showing  $p < 0.05$  *Egger, Harbord, Macaskill, Moreno, Peters, Rothstein, Rücker, Stanley*. Note that these tests fail even though treatment delay is uniformly distributed. In reality treatment delay is more complex — each trial has a different distribution of delays across patients, and the distribution across trials may be biased (e.g., late treatment trials may be more common). Similarly, many other variations in trials may produce asymmetry, including dose, administration, duration of treatment, differences in SOC, comorbidities, age, variants, and bias in design, implementation, analysis, and reporting.



**Figure 21.** Example funnel plot analysis for simulated perfect trials.

**Limitations.** Summary statistics from meta analysis necessarily lose information. As with all meta analyses, studies are heterogeneous, with differences in treatment delay, treatment regimen, patient demographics, variants, conflicts of interest, standard of care, and other factors. We provide analyses by specific outcomes and by treatment delay, and we aim to identify key characteristics in the forest plots and summaries. Results should be viewed in the context of study characteristics.

Some analyses classify treatment based on early or late administration, as done here, while others distinguish between mild, moderate, and severe cases. Viral load does not indicate degree of symptoms — for example patients may have a high viral load while being asymptomatic. With regard to treatments that have antiviral properties, timing of treatment is critical — late administration may be less helpful regardless of severity.

Details of treatment delay per patient is often not available. For example, a study may treat 90% of patients relatively early, but the events driving the outcome may come from 10% of patients treated very late. Our 5 day cutoff for early treatment may be too conservative, 5 days may be too late in many cases.

Comparison across treatments is confounded by differences in the studies performed, for example dose, variants, and conflicts of interest. Trials affiliated with special interests may use designs better suited to the preferred outcome.

In some cases, the most serious outcome has very few events, resulting in lower confidence results being used in pooled analysis, however the method is simpler and more transparent. This is less critical as the number of studies increases. Restriction to outcomes with sufficient power may be beneficial in pooled analysis and improve accuracy when there are few studies, however we maintain our pre-specified method to avoid any retrospective changes.

Studies show that combinations of treatments can be highly synergistic and may result in many times greater efficacy than individual treatments alone *Alsaidi, Andreani, De Forni (B), Fiaschi, Jeffreys (B), Jitobaom, Jitobaom (B), Ostrov, Said, Thairu, Wan*. Therefore standard of care may be critical and benefits may diminish or disappear if standard of care does not include certain treatments.

This real-time analysis is constantly updated based on submissions. Accuracy benefits from widespread review and submission of updates and corrections from reviewers. Less popular treatments may receive fewer reviews.

No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Efficacy may vary significantly with different variants and within different populations. All treatments have potential side effects. Propensity to experience side effects may be predicted in advance by qualified physicians. We do not provide medical advice. Before taking any medication, consult a qualified physician who can compare all options, provide personalized advice, and provide details of risks and benefits based on individual medical history and situations.

**Reviews.** *Bacigalupo et al.* present a review covering remdesivir for COVID-19.

## Conclusion


Meta analysis shows 7% [-1-14%] lower mortality, and pooled analysis using the most serious outcome reported shows 6% [-1-12%] lower risk, without reaching statistical significance. While studies to date show a small mortality improvement, meta regression with followup duration shows that this efficacy disappears with longer followup. There is also no benefit seen for mechanical ventilation, ICU admission, hospitalization, or progression. This may reflect antiviral efficacy being offset by side effects of treatment.

Studies show significantly increased risk of acute kidney injury *Gérard, Wu, Zhou*.

Prescription treatments have been preferentially used by patients at lower risk *Wilcock*. Retrospective studies may overestimate efficacy, for example patients with greater knowledge of effective treatments may be more likely to access prescription treatments but result in confounding because they are also more likely to use known beneficial non-prescription treatments.

## Study Notes


### Ader



Ader: RCT 857 hospitalized patients, showing no significant differences with remdesivir treatment. EudraCT2020-000936-23.

## Aghajani

### Remdesivir Aghajani et al. LATE TREATMENT




Is **late** treatment with remdesivir beneficial for COVID-19?

Retrospective 991 patients in Iran

Lower mortality with remdesivir (not stat. sig.,  $p=0.49$ )


c19early.org Aghajani et al., J. Medical Virology, Apr 2021



Aghajani: Retrospective 991 hospitalized patients in Iran focusing on aspirin use but also showing results for HCQ, remdesivir, and favipiravir.

## Ali

### Remdesivir CATCO LATE TREATMENT RCT




Is **late** treatment with remdesivir beneficial for COVID-19?

RCT 1,281 patients in Canada

Lower ventilation ( $p=0.00028$ ) and longer hospitalization ( $p=0.036$ )


c19early.org Ali et al., Canadian Medical Associati..., Jan 2022



Ali: RCT 1,282 hospitalized patients in Canada showing lower mechanical ventilation with remdesivir treatment, but no significant difference for mortality.

## Alshamrani

### Remdesivir Alshamrani et al. LATE TREATMENT



Is **late** treatment with remdesivir beneficial for COVID-19?

PSM retrospective 1,324 patients in Saudi Arabia (Mar 2020 - Jan 2021)


Lower mortality ( $p=0.0031$ ) and longer ICU admission ( $p=0.003$ )

c19early.org Alshamrani et al., Saudi Pharmaceutica..., Feb 2023




*Alshamrani*: PSM retrospective 29 hospitals in Saudi Arabia, showing lower mortality with remdesivir treatment.

## Amirizadeh



*Amirizadeh*: Retrospective 70 COVID-19 ICU patients, 35 receiving remdesivir plus standard treatment and 35 receiving standard treatment only. No significant differences were found for mortality, hospitalization time, ICU time, or ventilation time.


## Arch



*Arch*: Prospective PSM analysis of remdesivir use in the UK showing statistically significantly lower mortality at 28 days. For unspecified reasons, the study prioritized short-term outcomes. Mortality at 14 days was also lower but not statistically significant. Confounding by indication is likely and may only be partially addressed by the variables included in the PSM.

## Arfijanto

### Remdesivir Arfijanto et al. LATE TREATMENT




Is **late** treatment with remdesivir beneficial for COVID-19?

Retrospective 162 patients in Indonesia (June - December 2021)

No significant difference in viral clearance


c19early.org Arfijanto et al., Pathophysiology, May 2023



**Arfijanto:** Retrospective 162 hospitalized COVID-19 patients in Indonesia, showing no significant difference in delayed viral clearance with remdesivir treatment in unadjusted results.

## Aweimer

### Remdesivir Aweimer et al. INTUBATED PATIENTS




Is **very late** treatment with remdesivir beneficial for COVID-19?

Retrospective 149 patients in Germany (March 2020 - August 2021)

No significant difference in mortality


c19early.org Aweimer et al., Scientific Reports, Mar 2023



**Aweimer:** Retrospective 149 patients under invasive mechanical ventilation in Germany showing no significant difference in mortality with remdesivir in unadjusted results.

## Barrat-Due

### Remdesivir Barrat-Due et al. LATE TREATMENT DB RCT



Is **late** treatment with remdesivir beneficial for COVID-19?

Double-blind RCT 99 patients in Norway

Trial underpowered to detect differences


c19early.org Barrat-Due et al., Annals of Internal ..., Jul 2021



**Barrat-Due:** Small RCT in Norway with 52 HCQ and 42 remdesivir patients, showing no significant differences with treatment. Add-on trial to WHO Solidarity. NCT04321616.

## Bavaro


### Remdesivir for COVID-19 Bavaro et al. LATE TREATMENT



Is **late** treatment with remdesivir beneficial for COVID-19?  
Retrospective 331 patients in Italy (July 2021 - March 2022)

**Lower severe cases with remdesivir ( $p=0.00099$ )**


c19early.org Bavaro et al., Viruses, May 2023



**Bavaro:** Retrospective 331 hospitalized COVID-19 patients in Italy, showing lower progression with remdesivir. Combination therapy with mAbs was more effective, and improved results were seen for immunocompromised patients.

## Behboodikhah

### Remdesivir Behboodikhah et al. LATE TREATMENT




Is **late** treatment with remdesivir beneficial for COVID-19?

Retrospective 2,174 patients in Iran

Lower mortality with remdesivir (not stat. sig.,  $p=0.21$ )


c19early.org Behboodikhah et al., Iranian J. Scienc., Sep 2022



**Behboodikhah:** Retrospective 2,174 hospitalized patients showing no significant differences with remdesivir treatment.

## Beigel

### Remdesivir Beigel et al. LATE TREATMENT RCT




Is **late** treatment with remdesivir beneficial for COVID-19?

RCT 1,062 patients in the USA


**Improved recovery with remdesivir ( $p=0.0005$ )**

c19early.org Beigel et al., NEJM, October 2020




**Beigel:** RCT 1,062 hospitalized patients showing faster recovery time with treatment, median 10 days vs. 15 days for placebo, rate ratio for recovery 1.29,  $p<0.001$ . Day 29 mortality was 11.4% with remdesivir and 15.2% with placebo, hazard ratio HR 0.73 [0.52-1.03].

## Bowen




*Bowen*: Retrospective 4,631 hospitalized patients in New York, showing higher mortality with remdesivir, and lower mortality with HCQ. Authors suggest that increased mortality during the first epidemic wave was partly due to strain on hospital resources.

## Burhan



*Burhan*: Retrospective 559 COVID-19 ICU patients in Indonesia, showing higher mortality with remdesivir in unadjusted results, without statistical significance. Note that confounding by indication should be less significant for ICU studies compared to studies of all hospitalized patients, because all patients are in critical condition.


## Chang



*Chang*: Retrospective 209 hospitalized COVID-19 patients in Taiwan showing higher mortality with a 5-day course of remdesivir compared to other antivirals or no antiviral treatment in multivariable analysis. Adjustments include qSOFA and CCI, with the adjusted result decreasing risk by 3x, however adjustment may not fully account for confounding by severity.


## Chew

### Remdesivir for COVID-19 Chew et al. EARLY TREATMENT



Is early treatment with remdesivir beneficial for COVID-19?  
Retrospective 163 patients in Singapore (January - April 2020)  
Higher progression with remdesivir (not stat. sig.,  $p=0.4$ )


c19early.org Chew et al., Pathogens, March 2023



Chew: Retrospective 163 COVID-19 patients in Singapore, showing increased risk of liver injury (abnormal ALT) with acetaminophen in a dose-dependent manner, and with remdesivir, without statistical significance in both cases.

## Diaz


### Remdesivir for COVID-19 Diaz et al. LATE TREATMENT



Is late treatment with remdesivir beneficial for COVID-19?  
Retrospective 1,138 patients in the USA

Lower mortality with remdesivir ( $p=0.014$ )

c19early.org Diaz et al., Clinical Infectious Disea..., Aug 2021




Diaz: Retrospective 1138 hospitalized patients in the USA, 286 treated with remdesivir, showing lower mortality with treatment.

Age was not included in the adjustments (authors excluded variables that contributed to another score, in this case age is in Pneumonia Severity Index).

## El-Solh

### Remdesivir El-Solh et al. LATE TREATMENT



Is late treatment with remdesivir beneficial for COVID-19?  
Retrospective 643 patients in the USA

Lower mortality with remdesivir ( $p=0.031$ )

c19early.org El-Solh et al., J. Intensive Care Medi..., Oct 2020




El-Solh: Retrospective 7,816 Veterans Affairs hospitalized patients showing lower mortality with remdesivir.



## Elec

### Remdesivir for COVID-19 Elec et al. LATE TREATMENT



Is **late** treatment with remdesivir beneficial for COVID-19?

Retrospective 165 patients in Romania (March 2020 - May 2021)


**Higher ICU admission with remdesivir ( $p=0.01$ )**

c19early.org Elec et al., Int. J. Infectious Diseases, Mar 2022

**Elec:** Retrospective 165 hospitalized COVID-19+ kidney transplant patients, 38 treated with remdesivir, showing no significant difference in mortality, higher ICU admission, and lower ICU mortality. Subject to confounding by time with significant changes to SOC and treatment propensity during the study period.

## Elhadi

### Remdesivir for COVID-19 Elhadi et al. ICU PATIENTS



Is **very late** treatment with remdesivir beneficial for COVID-19?

Prospective study of 465 patients in Libya (May - December 2020)


No significant difference in mortality

c19early.org Elhadi et al., PLOS ONE, April 2021

**Elhadi:** Prospective study of 465 COVID-19 ICU patients in Libya showing no significant differences with treatment.

## Flisiak

### Remdesivir for COVID-19 SARSTer LATE TREATMENT



Is **late** treatment with remdesivir beneficial for COVID-19?


Retrospective 333 patients in Poland (March - August 2020)

**Greater improvement with remdesivir ( $p=0.01$ )**

c19early.org Flisiak et al., Polish Archives of Int., Nov 2020

**Flisiak:** Retrospective study comparing 122 remdesivir patients and 211 lopinavir/ritonavir patients, showing higher rates of clinical improvement with remdesivir and lower mortality (not statistically significant).


## Fried



*Fried*: Database analysis of 11,721 hospitalized patients, 48 treated with remdesivir.


Data inconsistencies have been found in this study, for example 99.4% of patients treated with HCQ were treated in urban hospitals, compared to 65% of untreated patients (Supplemental Table 3), while patients are distributed in a more balanced manner between teaching or not-teaching hospitals, as well as in the most urbanized (Northeast) and less urbanized (Midwest) regions of the United States [academic.oup.com](https://academic.oup.com).

## Garibaldi




*Garibaldi*: Retrospective 303 remdesivir patients and 303 matched controls showing significantly faster clinical improvement, and lower (but not statistically significant) mortality.

## Goldberg




**Goldberg:** Retrospective 29 remdesivir patients and 113 controls, not finding a significant difference in nasopharyngeal viral load or hospitalization time. Hospitalization time was lower with treatment, with a larger reduction for non-intubated patients, although not statistically significant in both cases.

## Gottlieb




**Gottlieb:** RCT high-risk outpatients, 279 treated with remdesivir and 283 control patients, median 5 days from symptoms, showing significantly lower hospitalization with treatment.

## Hagman




**Hagman:** Retrospective 318 hospitalized COVID-19 patients in Sweden, showing improvements in viral clearance but no improvement for mortality with remdesivir treatment.

## Hartantri




**Hartantri:** Retrospective 689 hospitalized patients in Indonesia, showing no significant difference in mortality with remdesivir treatment.

## Ho




**Ho:** Retrospective 26,445 hospitalized COVID-19 patients in the USA, showing higher mortality with remdesivir.

## Jamir




**Jamir:** Retrospective 266 COVID-19 ICU patients in India, showing significantly lower mortality with PVP-I oral gargling and topical nasal use, and non-statistically significant higher mortality with ivermectin and lower mortality with remdesivir.

## Jittamala




*Jittamala*: High conflict of interest RCT with very low risk patients with high existing immunity, showing faster viral clearance with remdesivir. The viral clearance half-life was very short in both arms. With rapid viral clearance and very low risk patients, the trial favors detecting an effect with intravenous treatments that have rapid onset of action.

## Kim




*Kim*: Retrospective 167 nosocomial COVID-19 patients in South Korea, showing higher mortality with remdesivir treatment, without statistical significance.

## Kneidinger




*Kneidinger*: Retrospective 218 COVID+ lung transplant patients in Germany, showing no significant difference in severe cases with early remdesivir use.

## Kuno




**Kuno:** PSM retrospective 3,372 hospitalized patients in the USA treated with steroids, showing no significant difference in mortality with remdesivir, but a lower risk of acute kidney injury.

## Kurniyanto



**Kurniyanto:** Retrospective 477 hospitalized patients in Indonesia, showing higher mortality with remdesivir in unadjusted results.

## Liao




**Liao:** Retrospective study of 215 critically ill COVID-19 patients with respiratory failure showing higher mortality for cancer patients. Remdesivir was used more for non-survivors, without statistical significance. Most patients received remdesivir, suggesting standard use for critically ill patients at the time, however it is not clear why some patients did not receive treatment, and baseline details per group are not provided.

## Madan


Madan:

## Madan




*Madan (B):* Retrospective 1,262 hospitalized patients, 398 treated with remdesivir, showing unadjusted lower mortality with treatment, and a treatment delay-response relationship.

## Mahajan




*Mahajan:* Small RCT with 34 remdesivir patients and 36 controls finding no significant difference in clinical outcomes.

## Malundo




**Malundo:** Retrospective 1,215 hospitalized patients in the Philippines, showing no significant difference in outcomes with remdesivir or HCQ use in unadjusted results subject to confounding by indication.

## Mitsushima



**Mitsushima:** Retrospective 18,566 hospitalized patients in Japan, showing higher mortality with remdesivir treatment.

## Mozaffari




**Mozaffari:** Retrospective 19,184 immunocompromised patients treated with remdesivir and matched controls, showing lower mortality with treatment. Several authors work at Gilead and the study was funded by Gilead.

The majority of patients were treated with remdesivir. A significant fraction of non-remdesivir patients may have contraindications that also increase risk. Authors provide serum creatine for 26% of the cohort, but notably provide only median and IQR, not allowing comparison of the number of patients with high values. Authors state that "renal function was not significantly different" between remdesivir and non-remdesivir patients, but this does not seem realistic given the prevalence of renal impairment and the contraindications for remdesivir.




## Mozaffari




*Mozaffari (B)*: Retrospective 28,855 remdesivir patients with PSM matched controls, showing lower mortality with treatment.

## Mulhem




*Mulhem*: Retrospective database analysis of 3,219 hospitalized patients in the USA. Very different results in the time period analysis (Table S2), and results significantly different to other studies for the same medications (e.g., heparin OR 3.06 [2.44-3.83]) suggest significant confounding by indication and confounding by time.

## Muntean




*Muntean*: Retrospective 551 severe/critical COVID-19 patients showing higher mortality and higher risk of drug induced liver injury with remdesivir. Authors appear to have reversed the OR for remdesivir - use was more common in non-survivors (61% vs. 50%). Authors report 116 patients treated with HCQ but provide no results for HCQ.

## Mustafa




**Mustafa:** Retrospective 444 hospitalized patients in Pakistan, showing lower mortality with remdesivir treatment in unadjusted results, not reaching statistical significance.

## Nadeem



**Nadeem:** Retrospective 132 hospitalized COVID-19 patients in the USA, showing no significant difference in mortality with remdesivir in unadjusted results.


## Ohl



**Ohl:** Retrospective 5,898 hospitalized patients in the USA, 2,374 receiving remdesivir treatment, showing no significant difference in mortality, and a longer time to hospital discharge with treatment.

## Oku

### Remdesivir for COVID-19 Oku et al. LATE TREATMENT



Is **late** treatment with remdesivir beneficial for COVID-19?

Retrospective 218 patients in Japan (June 2020 - June 2021)


Higher mortality with remdesivir (not stat. sig.,  $p=0.59$ )

c19early.org Oku et al., Modern Rheumatology, September 2022

Oku: Retrospective 220 COVID-19 patients with rheumatic disease in Japan, showing no significant difference in mortality with remdesivir treatment.

## Olender

### Remdesivir Olender et al. LATE TREATMENT



Is **late** treatment with remdesivir beneficial for COVID-19?

Retrospective 1,130 patients in the USA


**Lower mortality with remdesivir ( $p=0.001$ )**

c19early.org Olender et al., Clinical Infectious Di., Jul 2020

Olender: Comparative analysis between remdesivir trial GS-US-540-5773 and a retrospective SOC cohort with similar inclusion criteria, showing lower mortality and higher recovery at day 14 with remdesivir.

## Ong

### Remdesivir for COVID-19 Ong et al. EARLY TREATMENT



Is **early** treatment with remdesivir beneficial for COVID-19?

Retrospective 18 patients in Singapore


Slower recovery ( $p=0.6$ ) and longer hospitalization ( $p=0.31$ ), not sig.

c19early.org Ong et al., Acta Oncologica, January 2023

Ong: Retrospective 18 immunocompromised pediatric COVID-19 patients in Singapore, showing slower viral clearance with remdesivir, without statistical significance.

## Pasquini

### Remdesivir for COVID-19 Pasquini et al. ICU PATIENTS



Is **very late** treatment with remdesivir beneficial for COVID-19?

Retrospective 51 patients in Italy

**Lower mortality with remdesivir ( $p=0.03$ )**


c19early.org Pasquini et al., J. Antimicrobial Chem., Aug 2020



**Pasquini:** Retrospective 51 ICU patients under mechanical ventilation, 25 treated with remdesivir, showing lower mortality with treatment.

## Piccicacco

### Remdesivir Piccicacco et al. EARLY TREATMENT



Is **early** treatment with remdesivir beneficial for COVID-19?

Retrospective 172 patients in the USA (December 2021 - February 2022)

**Fewer hosp./ER visits ( $p=0.05$ ) and lower progression ( $p=0.034$ )**

c19early.org Piccicacco et al., J. Antimicrobial Ch., Aug 2022



**Piccicacco:** Retrospective high-risk outpatients in the USA, 82 treated with remdesivir, 88 with sotrovimab, and 90 control patients, showing significantly lower combined hospitalization/ER visits with both treatments in unadjusted results. The dominant variant was omicron B.1.1.529.

## Pourhoseingholi

### Remdesivir Pourhoseingholi et al. LATE TREATMENT




Is **late** treatment with remdesivir beneficial for COVID-19?

Prospective study of 2,468 patients in Iran (Feb - Jul 2020)


No significant difference in mortality

c19early.org Pourhoseingholi et al., Research Square, May 2021




**Pourhoseingholi:** Prospective study of 2,468 hospitalized COVID-19 patients in Iran, showing no significant difference with remdesivir treatment. IR.MUQ.REC.1399.013.

## Punzalan




*Punzalan*: Prospective study of 400 hospitalized patients in the Philippines, showing higher progression with remdesivir in unadjusted results, without statistical significance.

## Raad




*Raad*: Retrospective 3,966 COVID-19 patients, 1,115 with cancer, showing lower mortality with remdesivir and higher mortality with convalescent plasma.

## Salehi




*Salehi*: Retrospective 125 mechanically ventilated ICU patients in Iran, showing lower mortality with remdesivir treatment in unadjusted results.

## Schmidt




*Schmidt*: Retrospective 1,106 prostate cancer patients, showing higher mortality with remdesivir treatment.

## Seah




*Seah*: Retrospective 15 pediatric patients hospitalized for severe COVID-19 requiring oxygen and high dependency/intensive care unit (HD/ICU) admission in Singapore, showing no improvement in deescalation from HD/ICU care with remdesivir, however the remdesivir group had higher disease severity.

## Shamsi



*Shamsi*: Retrospective 183 hospitalized pediatric COVID-19 patients in Iran, showing no significant difference in mortality with remdesivir in unadjusted results.

### Remdesivir for COVID-19 Siraj et al. LATE TREATMENT




Is **late** treatment with remdesivir beneficial for COVID-19?

Retrospective 1,000 patients in India (March - December 2020)

**Lower mortality with remdesivir ( $p < 0.000001$ )**


c19early.org Siraj et al., Indian J. Clinical Pract., Feb 2022



**Siraj:** Retrospective 1,000 COVID+ hospitalized patients in India, showing lower mortality with famotidine and remdesivir in multivariable logistic regression.

### Sokolski

#### Remdesivir Sokolski et al. LATE TREATMENT




Is **late** treatment with remdesivir beneficial for COVID-19?

Retrospective 548 patients in Poland

No significant difference in mortality


c19early.org Sokolski et al., Scientific Reports, Feb 2024



**Sokolski:** Retrospective 2,170 hospitalized COVID-19 patients showing no difference in mortality with remdesivir in unadjusted results.

### SOLIDARITY Trial Consortium

#### Remdesivir SOLIDARITY LATE TREATMENT RCT



Is **late** treatment with remdesivir beneficial for COVID-19?

RCT 5,451 patients in multiple countries


No significant difference in mortality

c19early.org SOLIDARITY Trial Consortium, NEJM, Oct 2020



**SOLIDARITY Trial Consortium:** WHO SOLIDARITY open-label RCT with 2,750 very late stage (76% on oxygen/ventilation) remdesivir patients, mortality relative risk RR 0.95 [0.81-1.11],  $p = 0.50$ . Non-ventilated patients show a greater benefit, RR 0.86 [0.72-1.04],  $p = 0.13$ .


## Spinner



**Spinner:** Late stage (median 8 days from symptom onset) RCT 584 patients with moderate COVID-19 showing (non-statistically significant) lower mortality.


5-day remdesivir had significantly higher odds of a better clinical status distribution on the 7-point ordinal scale, odds ratio OR 1.65,  $p=0.02$ . The difference for 10-day remdesivir was not statistically significant,  $p=0.18$ .

## Tsuzuki



**Tsuzuki:** Retrospective database analysis of 12,487 hospitalized patients in Japan, showing lower risk of oxygen requirement, but no significant difference in mortality or ventilation/ECMO.

## Ullah






**Ullah:** Small late stage (hospitalized, <12 days symptoms) remdesivir study showing non-statistically significant higher mortality with treatment.

No adjustments were made for differences in the groups. Remdesivir mean age was 49 vs. control 57. Baseline oxygen requirement was 13.4 liters treatment vs. 10.8 control. Potential confounding by indication.


## Wang




**Wang:** Small RCT with 237 hospitalized patients in China with severe COVID-19, not showing statistically significant benefits. 158 treatment patients and 79 control patients.

While too small for significance, the subgroup treated within 10 days showed reduced mortality RR 0.76,  $p = 0.58$ , and reduced median time to clinical improvement of 18 days vs. 23 days, hazard ratio 1.52 [0.95-2.43].

## Yeramaneni



**Yeramaneni:** Retrospective 7,158 hospitalized COVID-19 patients in the USA analyzing famotidine treatment, showing no significant difference in mortality with associated remdesivir treatment.



**Zangeneh:** Retrospective 193 ICU patients in Iran, showing lower mortality with remdesivir treatment, not reaching statistical significance.

## Appendix 1. Methods and Data

We perform ongoing searches of PubMed, medRxiv, Europe PMC, ClinicalTrials.gov, The Cochrane Library, Google Scholar, Research Square, ScienceDirect, Oxford University Press, the reference lists of other studies and meta-analyses, and submissions to the site c19early.org. Search terms are remdesivir and COVID-19 or SARS-CoV-2. Automated searches are performed twice daily, with all matches reviewed for inclusion. All studies regarding the use of remdesivir for COVID-19 that report a comparison with a control group are included in the main analysis. Sensitivity analysis is performed, excluding studies with major issues, epidemiological studies, and studies with minimal available information. This is a living analysis and is updated regularly.

We extracted effect sizes and associated data from all studies. If studies report multiple kinds of effects then the most serious outcome is used in pooled analysis, while other outcomes are included in the outcome specific analyses. For example, if effects for mortality and cases are both reported, the effect for mortality is used, this may be different to the effect that a study focused on. If symptomatic results are reported at multiple times, we used the latest time, for example if mortality results are provided at 14 days and 28 days, the results at 28 days have preference. Mortality alone is preferred over combined outcomes. Outcomes with zero events in both arms are not used, the next most serious outcome with one or more events is used. For example, in low-risk populations with no mortality, a reduction in mortality with treatment is not possible, however a reduction in hospitalization, for example, is still valuable. Clinical outcomes are considered more important than viral test status. When basically all patients recover in both treatment and control groups, preference for viral clearance and recovery is given to results mid-recovery where available. After most or all patients have recovered there is little or no room for an effective treatment to do better, however faster recovery is valuable. If only individual symptom data is available, the most serious symptom has priority, for example difficulty breathing or low  $\text{SpO}_2$  is more important than cough. When results provide an odds ratio, we compute the relative risk when possible, or convert to a relative risk according to [Zhang](#). Reported confidence intervals and  $p$ -values were used when available, using adjusted values when provided. If multiple types of adjustments are reported propensity score matching and multivariable regression has preference over propensity score matching or weighting, which has preference over multivariable regression. Adjusted results have preference over unadjusted results for a more serious outcome when the adjustments significantly alter results. When needed, conversion between reported  $p$ -values and confidence intervals followed [Altman, Altman \(B\)](#), and Fisher's exact test was used to calculate  $p$ -values for event data. If continuity correction for zero values is required, we use the reciprocal of the opposite arm with the sum of the correction factors equal to 1 [Sweeting](#). Results are expressed with  $\text{RR} < 1.0$  favoring treatment, and using the risk of a negative outcome when applicable (for example, the risk of death rather than the risk of survival). If studies only report relative continuous values such as relative times, the ratio of the time for the treatment group versus the time for the control group is used. Calculations are done in Python (3.12.2) with scipy (1.12.0), pythonmeta (1.26), numpy (1.26.4), statsmodels (0.14.1), and plotly (5.19.0).

Forest plots are computed using PythonMeta <sup>Deng</sup> with the DerSimonian and Laird random effects model (the fixed effect assumption is not plausible in this case) and inverse variance weighting. Results are presented with 95% confidence intervals. Heterogeneity among studies was assessed using the  $I^2$  statistic. Mixed-effects meta-regression results are computed with R (4.1.2) using the metafor (3.0-2) and rms (6.2-0) packages, and using the most serious sufficiently powered outcome. For all statistical tests, a p-value less than 0.05 was considered statistically significant. Grobid 0.8.0 is used to parse PDF documents.

We have classified studies as early treatment if most patients are not already at a severe stage at the time of treatment (for example based on oxygen status or lung involvement), and treatment started within 5 days of the onset of symptoms. If studies contain a mix of early treatment and late treatment patients, we consider the treatment time of patients contributing most to the events (for example, consider a study where most patients are treated early but late treatment patients are included, and all mortality events were observed with late treatment patients). We note that a shorter time may be preferable. Antivirals are typically only considered effective when used within a shorter timeframe, for example 0-36 or 0-48 hours for oseltamivir, with longer delays not being effective <sup>McLean, Treanor</sup>.

We received no funding, this research is done in our spare time. We have no affiliations with any pharmaceutical companies or political parties.

A summary of study results is below. Please submit updates and corrections at <https://c19early.org/smeta.html>.

## Early treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

<i>Chew</i> , 3/16/2023, retrospective, Singapore, peer-reviewed, median age 56.0, 7 authors, study period 23 January, 2020 - 15 April, 2020.	abnormal ALT, 68.0% higher, OR 1.68, $p = 0.40$ , treatment 12, control 151, adjusted per study, multivariable, RR approximated with OR.
<i>Gottlieb</i> , 12/22/2021, Double Blind Randomized Controlled Trial, multiple countries, peer-reviewed, 30 authors, study period 18 September, 2020 - 8 April, 2021, average treatment delay 5.0 days, trial NCT04501952 (history) (PINETREE).	risk of death/hospitalization, 87.0% lower, RR 0.13, $p = 0.008$ , treatment 2 of 279 (0.7%), control 15 of 283 (5.3%), NNT 22, adjusted per study, COVID-19 related hospitalization or death from any cause @day 28, primary outcome.
	risk of hospitalization, 71.8% lower, RR 0.28, $p = 0.009$ , treatment 5 of 279 (1.8%), control 18 of 283 (6.4%), NNT 22.
	risk of no recovery, 29.1% lower, RR 0.71, $p = 0.31$ , treatment 43 of 66 (65.2%), control 45 of 60 (75.0%), adjusted per study, inverted to make $RR < 1$ favor treatment, alleviation of symptoms @day 14.
	risk of no recovery, 47.9% lower, RR 0.52, $p = 0.003$ , treatment 108 of 169 (63.9%), control 132 of 165 (80.0%), NNT 6.2, adjusted per study, inverted to make $RR < 1$ favor treatment, post-hoc alleviation of symptoms @day 14.
<i>Jittamala</i> , 7/20/2023, Randomized Controlled Trial, multiple countries, peer-reviewed, median age 30.1, 42 authors, study period 30 September, 2021 - 10 June, 2022, trial NCT05041907 (history) (PLATCOV).	risk of hospitalization, 66.3% lower, RR 0.34, $p = 1.00$ , treatment 0 of 67 (0.0%), control 1 of 69 (1.4%), NNT 69, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	relative clearance half-life, 28.9% better, RR 0.71, $p < 0.001$ , treatment median 12.8 IQR 8.0 $n=67$ , control median 18.0 IQR 10.5 $n=69$ , primary outcome.

<i>Kneidinger</i> , 9/9/2022, retrospective, Germany, peer-reviewed, 11 authors, study period 1 January, 2022 - 20 March, 2022, lung transplant patients.	risk of severe case, 19.9% lower, RR 0.80, $p = 0.71$ , treatment 6 of 46 (13.0%), control 28 of 172 (16.3%), NNT 31.
<i>Madan</i> , 7/19/2021, retrospective, India, preprint, 22 authors, early treatment subset, excluded in exclusion analyses: unadjusted results with no group details.	risk of death, 65.6% lower, RR 0.34, $p = 0.04$ , treatment 4 of 112 (3.6%), control 27 of 260 (10.4%), NNT 15, unadjusted, <5 days from onset.
<i>Ong</i> , 1/20/2023, retrospective, Singapore, peer-reviewed, 12 authors.	recovery time, 75.0% higher, relative time 1.75, $p = 0.60$ , treatment 4, control 14, defervescence.
	hospitalization time, 55.6% higher, relative time 1.56, $p = 0.31$ , treatment 4, control 14.
	time to viral-, 60.7% higher, relative time 1.61, $p = 0.14$ , treatment 4, control 14.
<i>Piccicacco</i> , 8/1/2022, retrospective, USA, peer-reviewed, 7 authors, study period 27 December, 2021 - 4 February, 2022, average treatment delay 4.0 days, ER visit.	risk of death, 65.6% lower, RR 0.34, $p = 1.00$ , treatment 0 of 82 (0.0%), control 1 of 90 (1.1%), NNT 90, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 29.
	risk of hospitalization, 30.2% lower, RR 0.70, $p = 0.47$ , treatment 7 of 82 (8.5%), control 11 of 90 (12.2%), NNT 27, day 29.
	risk of hospitalization/ER, 52.5% lower, RR 0.48, $p = 0.05$ , treatment 9 of 82 (11.0%), control 21 of 90 (23.3%), NNT 8.1, odds ratio converted to relative risk, day 29.
	risk of progression, 78.0% lower, RR 0.22, $p = 0.03$ , treatment 2 of 82 (2.4%), control 10 of 90 (11.1%), NNT 12, day 29.
<i>Seah</i> , 12/14/2023, retrospective, Singapore, peer-reviewed, median age 2.5, 9 authors, study period 1 January, 2020 - 18 March, 2022, excluded in exclusion analyses: unadjusted results with significant baseline differences.	no deescalation, 128.6% higher, RR 2.29, $p = 0.57$ , treatment 2 of 7 (28.6%), control 1 of 8 (12.5%), day 5.

## Late treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

<i>Ader</i> , 9/14/2021, Randomized Controlled Trial, multiple countries, peer-reviewed, 17 authors, study period 22 March, 2020 - 21 January, 2021, average treatment delay 9.0 days, trial NCT04315948 (history) (DISCOVERY).	risk of death, 6.4% lower, RR 0.94, $p = 0.77$ , treatment 34 of 414 (8.2%), control 37 of 418 (8.9%), NNT 156, adjusted per study, odds ratio converted to relative risk, day 28.
	risk of death, 11.7% lower, RR 0.88, $p = 0.76$ , treatment 21 of 414 (5.1%), control 24 of 418 (5.7%), NNT 149, day 15.
	risk of 7-point scale, 9.9% lower, OR 0.90, $p = 0.39$ , treatment 414, control 418, inverted to make OR<1 favor treatment, 28 days, RR approximated with OR.

	<p>risk of 7-point scale, 2.0% higher, OR 1.02, <math>p = 0.85</math>, treatment 414, control 418, inverted to make <math>OR &lt; 1</math> favor treatment, 15 days, RR approximated with OR.</p>
<p><i>Aghajani</i>, 4/29/2021, retrospective, Iran, peer-reviewed, 7 authors.</p>	<p>risk of death, 18.6% lower, HR 0.81, <math>p = 0.49</math>, treatment 46, control 945, univariate Cox proportional regression.</p>
<p><i>Ali</i>, 1/19/2022, Randomized Controlled Trial, Canada, peer-reviewed, 85 authors, average treatment delay 8.0 days, trial NCT04330690 (history) (CATCO).</p>	<p>risk of death, 12.0% lower, RR 0.88, <math>p = 0.21</math>, treatment 127 of 634 (20.0%), control 152 of 647 (23.5%), NNT 29, day 60.</p>
	<p>risk of death, 17.0% lower, RR 0.83, <math>p = 0.09</math>, treatment 117 of 634 (18.5%), control 145 of 647 (22.4%), NNT 25, in hospital.</p>
	<p>risk of death, 20.6% lower, RR 0.79, <math>p = 0.59</math>, treatment 14 of 634 (2.2%), control 18 of 647 (2.8%), NNT 174, day 15.</p>
	<p>risk of mechanical ventilation, 47.0% lower, RR 0.53, <math>p &lt; 0.001</math>, treatment 46 of 634 (7.3%), control 89 of 647 (13.8%), NNT 15, day 60.</p>
	<p>risk of no recovery, 9.0% lower, RR 0.91, <math>p = 0.41</math>, treatment 634, control 647, clinical status, day 60.</p>
	<p>hospitalization time, 11.1% higher, relative time 1.11, <math>p = 0.04</math>, treatment median 10.0 IQR 12.0 <math>n=634</math>, control median 9.0 IQR 11.0 <math>n=647</math>.</p>
<p><i>Alshamrani</i>, 2/15/2023, retrospective, Saudi Arabia, peer-reviewed, 3 authors, study period March 2020 - January 2021.</p>	<p>risk of death, 17.3% lower, RR 0.83, <math>p = 0.003</math>, treatment 137 of 246 (55.7%), control 725 of 1,078 (67.3%), NNT 8.6, adjusted per study, odds ratio converted to relative risk, propensity score matching, multivariable.</p>
	<p>risk of progression, 4.3% lower, RR 0.96, <math>p = 0.12</math>, treatment 215 of 246 (87.4%), control 984 of 1,078 (91.3%), NNT 26, adjusted per study, odds ratio converted to relative risk, AKI, ARDS, multi-organ failure, or mortality, propensity score matching, multivariable.</p>
	<p>ICU time, 42.6% higher, relative time 1.43, <math>p = 0.003</math>, treatment 245, control 995, propensity score matching.</p>
	<p>hospitalization time, 7.4% lower, relative time 0.93, <math>p = 0.25</math>, treatment 246, control 1,078, propensity score matching.</p>
<p><i>Amirizadeh</i>, 11/1/2023, retrospective, Iran, peer-reviewed, 5 authors, average treatment delay 8.04 (treatment) 7.45 (control) days.</p>	<p>risk of death, 3.3% higher, RR 1.03, <math>p = 1.00</math>, treatment 31 of 35 (88.6%), control 30 of 35 (85.7%).</p>
	<p>ventilation time, 52.2% higher, relative time 1.52, <math>p = 0.17</math>, treatment mean 7.03 (<math>\pm 8.92</math>) <math>n=35</math>, control mean 4.62 (<math>\pm 5.24</math>) <math>n=35</math>.</p>
	<p>ICU time, 27.0% higher, relative time 1.27, <math>p = 0.23</math>, treatment mean 14.03 (<math>\pm 11.55</math>) <math>n=35</math>, control mean 11.05 (<math>\pm 9.1</math>) <math>n=35</math>.</p>
	<p>hospitalization time, 24.2% higher, relative time 1.24, <math>p = 0.22</math>, treatment mean 16.11 (<math>\pm 11.52</math>) <math>n=35</math>, control mean 12.97</p>

	(±9.65) n=35.
<i>Arch</i> , 6/21/2021, prospective, propensity score matching, United Kingdom, preprint, 10 authors, average treatment delay 6.0 days.	risk of death, 19.9% lower, RR 0.80, $p = 0.03$ , treatment 203 of 1,491 (13.6%), control 777 of 4,676 (16.6%), NNT 33, odds ratio converted to relative risk, PSM, day 28.
	risk of death, 18.0% lower, RR 0.82, $p = 0.12$ , treatment 140 of 1,502 (9.3%), control 565 of 4,728 (12.0%), NNT 38, odds ratio converted to relative risk, PSM, day 14.
	risk of mechanical ventilation, 68.0% higher, RR 1.68, $p = 0.003$ , treatment 106 of 1,498 (7.1%), control 153 of 4,602 (3.3%), odds ratio converted to relative risk, PSM, day 28.
<i>Arfijanto</i> , 5/4/2023, retrospective, Indonesia, peer-reviewed, 8 authors, study period June 2021 - December 2021, excluded in exclusion analyses: unadjusted results with no group details.	delayed viral clearance, 0.9% lower, RR 0.99, $p = 1.00$ , treatment 17 of 44 (38.6%), control 46 of 118 (39.0%), NNT 288.
<i>Aweimer</i> , 3/29/2023, retrospective, Germany, peer-reviewed, median age 67.0, 19 authors, study period 1 March, 2020 - 31 August, 2021.	risk of death, 13.0% higher, RR 1.13, $p = 0.33$ , treatment 40 of 51 (78.4%), control 68 of 98 (69.4%), day 100.
<i>Barrat-Due</i> , 7/13/2021, Double Blind Randomized Controlled Trial, Norway, peer-reviewed, 41 authors, average treatment delay 8.0 days, trial NCT04321616 (history).	risk of death, no change, RR 1.00, $p = 1.00$ , treatment 3 of 42 (7.1%), control 4 of 57 (7.0%), adjusted per study.
	risk of death, 35.7% higher, RR 1.36, $p = 0.70$ , treatment 3 of 42 (7.1%), control 3 of 57 (5.3%), day 60.
	risk of death, 54.8% lower, RR 0.45, $p = 0.63$ , treatment 1 of 42 (2.4%), control 3 of 57 (5.3%), NNT 35, day 28.
<i>Bavaro</i> , 5/19/2023, retrospective, Italy, peer-reviewed, median age 75.0, 27 authors, study period 1 July, 2021 - 15 March, 2022.	risk of severe case, 7.0% lower, RR 0.93, $p < 0.001$ , treatment 120, control 211, propensity score weighting.
<i>Behboodikhah</i> , 9/15/2022, retrospective, Iran, peer-reviewed, 8 authors.	risk of death, 37.5% lower, OR 0.62, $p = 0.21$ , treatment 1,214, control 960, adjusted per study, multivariable, RR approximated with OR.
<i>Beigel</i> , 10/8/2020, Randomized Controlled Trial, USA, peer-reviewed, 12 authors, average treatment delay 9.0 days.	risk of death, 27.0% lower, HR 0.73, $p = 0.07$ , treatment 541, control 521, day 29.
	risk of death, 45.0% lower, HR 0.55, $p = 0.005$ , treatment 541, control 521, day 15.
	risk of no recovery, 22.5% lower, RR 0.78, $p < 0.001$ , treatment 541, control 521, inverted to make $RR < 1$ favor treatment.
<i>Bowen</i> , 8/25/2022, retrospective, USA, peer-reviewed, 10 authors, study period 1 March, 2020 - 31 March, 2021.	risk of death, 57.0% higher, HR 1.57, $p < 0.001$ , treatment 817, control 3,814, Table S2, Cox proportional hazards, day 30.
<i>Burhan</i> , 9/25/2023, retrospective, Indonesia, peer-reviewed, 26 authors, study period January 2020 - March 2021.	risk of death, 14.8% higher, RR 1.15, $p = 0.23$ , treatment 33 of 43 (76.7%), control 345 of 516 (66.9%).

<i>Chang</i> , 12/29/2023, retrospective, Taiwan, peer-reviewed, 2 authors.	risk of death, 184.7% higher, OR 2.85, $p = 0.04$ , treatment 81, control 81, adjusted per study, multivariable, RR approximated with OR.
<i>Diaz</i> , 8/19/2021, retrospective, USA, peer-reviewed, 45 authors.	risk of death, 34.7% lower, HR 0.65, $p = 0.01$ , treatment 33 of 286 (11.5%), control 173 of 852 (20.3%), NNT 11, adjusted per study, odds ratio converted to relative risk, multivariable, Cox proportional hazards, day 60.
	risk of death, 44.0% lower, HR 0.56, $p = 0.04$ , treatment 286, control 852, adjusted per study, multivariable, Cox proportional hazards, day 30, RR approximated with OR.
<i>El-Solh</i> , 10/20/2020, retrospective, database analysis, USA, peer-reviewed, 5 authors, excluded in exclusion analyses: very late stage, >50% on oxygen/ventilation at baseline; substantial unadjusted confounding by indication likely; significant confounding by contraindications possible.	risk of death, 29.0% lower, HR 0.71, $p = 0.03$ , treatment 63 of 219 (28.8%), control 202 of 424 (47.6%), NNT 5.3, adjusted per study, multivariable.
<i>Elec</i> , 3/14/2022, retrospective, Romania, peer-reviewed, 9 authors, study period 1 March, 2020 - 31 May, 2021, excluded in exclusion analyses: substantial confounding by time possible due to significant changes in SOC and treatment propensity during the study period.	risk of death, 19.3% lower, RR 0.81, $p = 0.66$ , treatment 7 of 38 (18.4%), control 29 of 127 (22.8%), NNT 23.
	risk of mechanical ventilation, 10.9% lower, RR 0.89, $p = 0.73$ , treatment 8 of 38 (21.1%), control 30 of 127 (23.6%), NNT 39.
	risk of ICU admission, 71.9% higher, RR 1.72, $p = 0.01$ , treatment 18 of 38 (47.4%), control 35 of 127 (27.6%).
<i>Elhadi</i> , 4/30/2021, prospective, Libya, peer-reviewed, 21 authors, study period 29 May, 2020 - 30 December, 2020, excluded in exclusion analyses: unadjusted results with no group details.	risk of death, 10.9% higher, RR 1.11, $p = 0.65$ , treatment 14 of 21 (66.7%), control 267 of 444 (60.1%), day 60.
<i>Flisiak</i> , 11/3/2020, retrospective, Poland, peer-reviewed, 23 authors, study period 1 March, 2020 - 31 August, 2020, SARSTer trial.	risk of death, 48.9% lower, RR 0.51, $p = 0.18$ , treatment 5 of 122 (4.1%), control 17 of 211 (8.1%), NNT 25, odds ratio converted to relative risk, all patients, day 28.
	no clinical improvement, 56.5% lower, RR 0.44, $p = 0.01$ , treatment 9 of 122 (7.4%), control 36 of 211 (17.1%), NNT 10, odds ratio converted to relative risk.
<i>Fried</i> , 8/28/2020, retrospective, database analysis, USA, peer-reviewed, 11 authors, excluded in exclusion analyses: excessive unadjusted differences between groups; substantial unadjusted confounding by indication likely.	risk of death, 61.2% lower, RR 0.39, $p = 0.02$ , treatment 4 of 48 (8.3%), control 2,510 of 11,673 (21.5%), NNT 7.6, remdesivir vs. non-remdesivir.
	risk of mechanical ventilation, 36.8% higher, RR 1.37, $p = 0.25$ , treatment 11 of 48 (22.9%), control 1,956 of 11,673 (16.8%), remdesivir vs. non-remdesivir.
<i>Garibaldi</i> , 11/20/2020, retrospective, USA, preprint, 10 authors.	risk of death, 20.0% lower, HR 0.80, $p = 0.44$ , treatment 23 of 303 (7.6%), control 45 of 303 (14.9%), adjusted per study, day 28.



	<p>risk of no improvement, 35.0% better, RR 0.65, <math>p &lt; 0.001</math>, treatment 52 of 303 (17.2%), control 80 of 303 (26.4%), NNT 11, adjusted per study, day 28.</p>
<p><i>Goldberg</i>, 3/9/2021, retrospective, Israel, peer-reviewed, 7 authors.</p>	<p>hospitalization time, 9.2% lower, relative time 0.91, <math>p = 0.77</math>, treatment 29, control 113.</p>
	<p>risk of no viral clearance, 0.1% lower, RR 1.00, <math>p = 0.98</math>, treatment 29, control 113, relative change in Ct values.</p>
<p><i>Hagman</i>, 9/26/2023, retrospective, Sweden, peer-reviewed, 9 authors, average treatment delay 6.0 days.</p>	<p>risk of death, no change, HR 1.00, <math>p = 0.97</math>, treatment 105, control 213, adjusted per study, multivariable, day 60.</p>
	<p>risk of death, no change, HR 1.00, <math>p = 0.99</math>, treatment 105, control 213, adjusted per study, multivariable, day 28.</p>
	<p>risk of death, 20.0% lower, HR 0.80, <math>p = 0.74</math>, treatment 105, control 213, adjusted per study, multivariable, day 7.</p>
	<p>risk of progression, 40.0% higher, OR 1.40, <math>p = 0.31</math>, treatment 105, control 213, adjusted per study, multivariable, Table S7, RR approximated with OR.</p>
	<p>risk of no viral clearance, 28.6% lower, HR 0.71, <math>p = 0.11</math>, treatment 105, control 213, adjusted per study, inverted to make <math>HR &lt; 1</math> favor treatment, multivariable.</p>
<p><i>Hartantri</i>, 2/9/2023, retrospective, Indonesia, peer-reviewed, 10 authors, study period 1 March, 2020 - 31 December, 2020.</p>	<p>risk of death, 11.0% lower, HR 0.89, <math>p = 0.84</math>, adjusted per study, mild/moderate, multivariable, Cox proportional hazards.</p>
	<p>risk of death, 24.0% lower, HR 0.76, <math>p = 0.53</math>, adjusted per study, severe, multivariable, Cox proportional hazards.</p>
<p><i>Ho</i>, 10/31/2023, retrospective, USA, peer-reviewed, 9 authors, study period 1 January, 2020 - 31 August, 2021.</p>	<p>risk of death, 62.0% higher, OR 1.62, <math>p &lt; 0.001</math>, treatment 5,294, control 21,151, adjusted per study, multivariable, RR approximated with OR.</p>
<p><i>Jamir</i>, 12/13/2021, retrospective, India, peer-reviewed, 6 authors, study period June 2020 - October 2020.</p>	<p>risk of death, 8.0% lower, HR 0.92, <math>p = 0.77</math>, treatment 60 of 181 (33.1%), control 41 of 85 (48.2%), NNT 6.6, adjusted per study, multivariable, Cox proportional hazards.</p>
<p><i>Kim</i>, 3/15/2023, retrospective, South Korea, peer-reviewed, 5 authors, study period 1 November, 2021 - 30 April, 2022.</p>	<p>risk of death, 1612.4% higher, RR 17.12, <math>p = 0.22</math>, treatment 14 of 145 (9.7%), control 0 of 22 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).</p>
<p><i>Kuno</i>, 8/9/2021, retrospective, propensity score matching, USA, peer-reviewed, 6 authors.</p>	<p>risk of death, 0.9% lower, RR 0.99, <math>p = 0.96</math>, treatment 214 of 999 (21.4%), control 216 of 999 (21.6%), NNT 499, PSM.</p>
	<p>risk of mechanical ventilation, no change, RR 1.00, <math>p = 1.00</math>, treatment 140 of 999 (14.0%), control 140 of 999 (14.0%), PSM.</p>
	<p>risk of ICU admission, 17.1% higher, RR 1.17, <math>p = 0.05</math>, treatment 260 of 999 (26.0%), control 222 of 999 (22.2%), PSM.</p>



<i>Kurniyanto</i> , 2/28/2022, retrospective, Indonesia, peer-reviewed, 11 authors, excluded in exclusion analyses: unadjusted results with no group details; substantial unadjusted confounding by indication likely.	risk of death, 460.0% higher, RR 5.60, $p < 0.001$ , treatment 7 of 45 (15.6%), control 12 of 432 (2.8%).
<i>Liao</i> , 1/15/2024, retrospective, Taiwan, peer-reviewed, median age 73.0, 10 authors, study period May 2022 - September 2022, excluded in exclusion analyses: unadjusted results with no group details.	risk of death, 25.4% higher, RR 1.25, $p = 0.67$ , treatment 37 of 59 (62.7%), control 3 of 6 (50.0%), day 120.
<i>Madan (B)</i> , 7/19/2021, retrospective, India, preprint, 22 authors, excluded in exclusion analyses: excessive unadjusted differences between groups.	risk of death, 44.4% lower, RR 0.56, $p = 0.03$ , treatment 23 of 398 (5.8%), control 27 of 260 (10.4%), NNT 22, unadjusted.
	risk of death, 65.6% lower, RR 0.34, $p = 0.04$ , treatment 4 of 112 (3.6%), control 27 of 260 (10.4%), NNT 15, unadjusted, <5 days from onset.
	risk of death, 61.7% lower, RR 0.38, $p = 0.009$ , treatment 9 of 226 (4.0%), control 27 of 260 (10.4%), NNT 16, unadjusted, 5-10 days from onset.
	risk of death, 60.5% higher, RR 1.60, $p = 0.18$ , treatment 10 of 60 (16.7%), control 27 of 260 (10.4%), unadjusted, >10 days from onset.
	risk of death, 31.0% lower, RR 0.69, $p = 0.30$ , treatment 19 of 398 (4.8%), control 18 of 260 (6.9%), NNT 47, day 14.
	risk of death, 34.7% lower, RR 0.65, $p = 0.32$ , treatment 14 of 398 (3.5%), control 14 of 260 (5.4%), NNT 54, day 10.
	risk of death, 47.7% lower, RR 0.52, $p = 0.22$ , treatment 8 of 398 (2.0%), control 10 of 260 (3.8%), NNT 54, day 7.
	risk of death, 34.7% lower, RR 0.65, $p = 0.53$ , treatment 5 of 398 (1.3%), control 5 of 260 (1.9%), NNT 150, day 5.
<i>Mahajan</i> , 3/20/2021, Randomized Controlled Trial, India, peer-reviewed, 3 authors, study period June 2020 - December 2020, average treatment delay 6.84 days.	risk of death, 76.5% higher, RR 1.76, $p = 0.47$ , treatment 5 of 34 (14.7%), control 3 of 36 (8.3%).
	risk of mechanical ventilation, 111.8% higher, RR 2.12, $p = 0.42$ , treatment 4 of 34 (11.8%), control 2 of 36 (5.6%).
<i>Malundo</i> , 7/14/2022, retrospective, Philippines, peer-reviewed, 16 authors, study period 12 March, 2021 - 9 September, 2021, excluded in exclusion analyses: unadjusted results with no group details.	risk of death, 16.5% higher, RR 1.17, $p = 0.45$ , treatment 24 of 115 (20.9%), control 197 of 1,100 (17.9%).
<i>Mitsushima</i> , 2/21/2023, retrospective, Japan, peer-reviewed, 3 authors.	risk of death, 44.0% higher, OR 1.44, $p < 0.01$ , adjusted per study, multivariable, RR approximated with OR.

<p><i>Mozaffari</i>, 8/9/2023, retrospective, USA, peer-reviewed, 11 authors, study period 1 December, 2020 - 30 April, 2022.</p>	<p>risk of death, 25.0% lower, HR 0.75, <math>p &lt; 0.001</math>, treatment 14,169, control 5,341, adjusted per study, propensity score matching, Cox proportional hazards, day 28.</p>
	<p>risk of death, 30.0% lower, HR 0.70, <math>p &lt; 0.001</math>, treatment 14,169, control 5,341, adjusted per study, propensity score matching, Cox proportional hazards, day 14.</p>
<p><i>Mozaffari (B)</i>, 10/1/2021, retrospective, USA, peer-reviewed, 12 authors.</p>	<p>risk of death, 12.0% lower, HR 0.88, <math>p = 0.003</math>, treatment 4,441 of 28,855 (15.4%), control 5,499 of 28,855 (19.1%), NNT 27, adjusted per study, PSM, Cox proportional hazards, day 28.</p>
	<p>risk of death, 24.0% lower, HR 0.76, <math>p &lt; 0.001</math>, treatment 3,057 of 28,855 (10.6%), control 4,437 of 28,855 (15.4%), NNT 21, adjusted per study, PSM, Cox proportional hazards, day 14.</p>
<p><i>Mulhem</i>, 4/7/2021, retrospective, database analysis, USA, peer-reviewed, 3 authors, excluded in exclusion analyses: substantial unadjusted confounding by indication likely; substantial confounding by time possible due to significant changes in SOC and treatment propensity during the study period.</p>	<p>risk of death, 85.7% higher, RR 1.86, <math>p = 0.54</math>, treatment 1 of 8 (12.5%), control 515 of 3,211 (16.0%), adjusted per study, odds ratio converted to relative risk, logistic regression.</p>
<p><i>Muntean</i>, 12/19/2023, retrospective, Romania, peer-reviewed, 8 authors.</p>	<p>risk of death, 45.1% higher, RR 1.45, <math>p = 0.03</math>, treatment 71 of 287 (24.7%), control 45 of 264 (17.0%).</p>
<p><i>Mustafa</i>, 12/29/2021, retrospective, Pakistan, peer-reviewed, 7 authors, excluded in exclusion analyses: unadjusted results with no group details.</p>	<p>risk of death, 32.7% lower, RR 0.67, <math>p = 0.21</math>, treatment 16 of 200 (8.0%), control 29 of 244 (11.9%), NNT 26.</p>
<p><i>Nadeem</i>, 8/12/2023, retrospective, USA, peer-reviewed, mean age 59.0, 6 authors, study period 1 March, 2020 - 28 February, 2022, excluded in exclusion analyses: unadjusted results with no group details.</p>	<p>risk of death, 12.5% higher, RR 1.12, <math>p = 1.00</math>, treatment 12 of 96 (12.5%), control 4 of 36 (11.1%).</p>
<p><i>Ohl</i>, 7/15/2021, retrospective, propensity score matching, USA, peer-reviewed, 9 authors.</p>	<p>risk of death, 6.0% higher, HR 1.06, <math>p = 0.66</math>, treatment 143 of 1,172 (12.2%), control 124 of 1,172 (10.6%), adjusted per study, PSM, Cox proportional hazards regression, day 30.</p>
	<p>hospitalization time, 100% higher, relative time 2.00, <math>p &lt; 0.001</math>, treatment 1,172, control 1,172, PSM, Cox proportional hazards regression.</p>
<p><i>Oku</i>, 9/6/2022, retrospective, Japan, peer-reviewed, 8 authors, study period 3 June, 2020 - 30 June, 2021, excluded in exclusion analyses: unadjusted results with no group details.</p>	<p>risk of death, 40.2% higher, RR 1.40, <math>p = 0.59</math>, treatment 3 of 46 (6.5%), control 8 of 172 (4.7%), unadjusted, odds ratio converted to relative risk.</p>
<p><i>Olender</i>, 7/24/2020, retrospective, USA, peer-reviewed, 33 authors.</p>	<p>risk of death, 58.8% lower, RR 0.41, <math>p = 0.001</math>, treatment 24 of 312 (7.7%), control 102 of 818 (12.5%), odds ratio converted to relative risk, weighted multivariable logistic regression, day 14.</p>
<p><i>Pasquini</i>, 8/23/2020, retrospective, Italy, peer-reviewed, 9 authors.</p>	<p>risk of death, 16.2% lower, RR 0.84, <math>p = 0.03</math>, treatment 14 of 25 (56.0%), control 24 of 26 (92.3%), NNT 2.8, adjusted per study, inverted to make <math>RR &lt; 1</math> favor treatment, odds ratio converted to</p>

	relative risk, multivariate.
<i>Pourhoseingholi</i> , 5/26/2021, prospective, Iran, preprint, mean age 57.9, 11 authors, study period 2 February, 2020 - 20 July, 2020, average treatment delay 7.4 days.	risk of death, 2.0% higher, HR 1.02, $p = 0.92$ , treatment 42 of 123 (34.1%), control 297 of 2,345 (12.7%), adjusted per study, multivariable, Cox proportional hazards.
<i>Punzalan</i> , 2/28/2023, prospective, Philippines, peer-reviewed, mean age 56.0, 17 authors, study period October 2020 - September 2021.	risk of death, 42.0% higher, RR 1.42, $p = 0.12$ , treatment 47 of 224 (21.0%), control 26 of 176 (14.8%).
	risk of progression, 58.9% higher, RR 1.59, $p = 0.001$ , treatment 93 of 224 (41.5%), control 46 of 176 (26.1%).
<i>Raad</i> , 8/26/2022, retrospective, multiple countries, preprint, 52 authors, study period January 2020 - November 2020.	risk of death, 42.0% lower, OR 0.58, $p = 0.009$ , adjusted per study, multivariable, day 30, RR approximated with OR.
<i>Salehi</i> , 3/11/2022, retrospective, Iran, preprint, mean age 62.0, 11 authors, study period April 2021 - September 2021, excluded in exclusion analyses: unadjusted results with no group details.	risk of death, 36.6% lower, RR 0.63, $p = 0.01$ , treatment 17 of 40 (42.5%), control 57 of 85 (67.1%), NNT 4.1.
<i>Schmidt</i> , 11/12/2021, retrospective, USA, peer-reviewed, 42 authors, study period 17 March, 2020 - 11 February, 2021, excluded in exclusion analyses: confounding by indication is likely and adjustments do not consider COVID-19 severity at baseline.	risk of severe case, 509.0% higher, OR 6.09, $p < 0.001$ , treatment 43, control 434, adjusted per study, propensity score matching, multivariable, RR approximated with OR.
<i>Shamsi</i> , 7/17/2023, retrospective, Iran, peer-reviewed, 4 authors, study period 1 March, 2020 - 1 August, 2021, excluded in exclusion analyses: unadjusted results with no group details.	risk of death, 22.6% higher, RR 1.23, $p = 0.63$ , treatment 8 of 53 (15.1%), control 16 of 130 (12.3%).
<i>Siraj</i> , 2/28/2022, retrospective, India, peer-reviewed, median age 56.0, 13 authors, study period March 2020 - December 2020.	risk of death, 52.9% lower, RR 0.47, $p < 0.001$ , treatment 108 of 413 (26.2%), control 197 of 587 (33.6%), adjusted per study, inverted to make $RR < 1$ favor treatment, odds ratio converted to relative risk, multivariable.
<i>Sokolski</i> , 2/28/2024, retrospective, Poland, peer-reviewed, 11 authors, excluded in exclusion analyses: unadjusted results with no group details.	risk of death, no change, HR 1.00, $p = 1.00$ , treatment 88, control 460, Cox proportional hazards, day 90.
<i>SOLIDARITY Trial Consortium</i> , 10/15/2020, Randomized Controlled Trial, multiple countries, peer-reviewed, 15 authors, trial NCT04315948 (history) (SOLIDARITY).	risk of death, 5.0% lower, RR 0.95, $p = 0.53$ , treatment 301 of 2,743 (11.0%), control 303 of 2,708 (11.2%), NNT 464, day 28.
<i>Spinner</i> , 8/21/2020, Randomized Controlled Trial, multiple countries, peer-reviewed, 30 authors, study period 15 March, 2020 - 18 April, 2020, average treatment delay 8.0 days.	5 or 10 day remdesivir vs. control 28 day mortality, 34.9% lower, RR 0.65, $p = 0.50$ , treatment 5 of 384 (1.3%), control 4 of 200 (2.0%), NNT 143, day 28.
<i>Tsuzuki</i> , 3/10/2021, retrospective, Japan, peer-reviewed, 21 authors, average treatment delay 6.0 days.	risk of death, 4.0% higher, HR 1.04, $p = 0.21$ , treatment 69 of 824 (8.4%), control 285 of 11,663 (2.4%), adjusted per study, day 30.

	<p>risk of mechanical ventilation or ECMO, 1.7% lower, HR 0.98, <math>p = 0.68</math>, treatment 48 of 824 (5.8%), control 98 of 11,663 (0.8%), adjusted per study.</p> <p>risk of progression, 15.0% lower, HR 0.85, <math>p = 0.68</math>, treatment 559 of 824 (67.8%), control 1,784 of 11,663 (15.3%), adjusted per study.</p>
Ullah, 11/29/2020, retrospective, Pakistan, peer-reviewed, 8 authors.	<p>risk of death, 100% higher, RR 2.00, <math>p = 0.33</math>, treatment 8 of 30 (26.7%), control 4 of 30 (13.3%).</p> <p>risk of mechanical ventilation, 250.0% higher, RR 3.50, <math>p = 0.15</math>, treatment 7 of 30 (23.3%), control 2 of 30 (6.7%).</p>
Wang, 4/29/2020, Randomized Controlled Trial, China, peer-reviewed, 46 authors, study period 6 February, 2020 - 12 March, 2020, average treatment delay 11.0 days.	<p>all patients, 8.6% higher, RR 1.09, <math>p = 1.00</math>, treatment 22 of 158 (13.9%), control 10 of 78 (12.8%), day 28.</p> <p>&lt;10 days from symptoms, 24.3% lower, RR 0.76, <math>p = 0.58</math>, treatment 8 of 71 (11.3%), control 7 of 47 (14.9%), NNT 28, day 28.</p> <p>&gt;10 days from symptoms, 47.6% higher, RR 1.48, <math>p = 0.76</math>, treatment 12 of 84 (14.3%), control 3 of 31 (9.7%), day 28.</p>
Yeramaneni, 2/28/2021, retrospective, USA, peer-reviewed, 6 authors, study period 11 February, 2020 - 8 May, 2020.	risk of death, 24.0% higher, OR 1.24, $p = 0.87$ , treatment 32, control 7,126, adjusted per study, multivariable, day 30, RR approximated with OR.
Zangeneh, 5/13/2022, retrospective, Iran, peer-reviewed, 3 authors.	risk of death, 32.0% lower, HR 0.68, $p = 0.06$ , Cox proportional hazards.

## Supplementary Data

Supplementary Data

## Footnotes

- a. Viral infection and replication involves attachment, entry, uncoating and release, genome replication and transcription, translation and protein processing, assembly and budding, and release. Each step can be disrupted by therapeutics.

## References

1. **academic.oup.com**, [academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1618/5934822](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1618/5934822).
2. **Ader et al.**, *Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial*, *Lancet Infectious Diseases*, doi:10.1016/S1473-3099(21)00485-0.
3. **Aghajani et al.**, *Decreased In-Hospital Mortality Associated with Aspirin Administration in Hospitalized Patients Due to Severe COVID-19*, *Journal of Medical Virology*, doi:10.1002/jmv.27053.

4. **Ali** et al., *Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial*, Canadian Medical Association Journal, doi:10.1503/cmaj.211698.
5. **Als-Nielsen** et al., *Association of Funding and Conclusions in Randomized Drug Trials*, JAMA, doi:10.1001/jama.290.7.921.
6. **Alsaïdi** et al., *Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model*, Marine Drugs, doi:10.3390/md19080418.
7. **Alshamrani** et al., *Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study*, Saudi Pharmaceutical Journal, doi:10.1016/j.jsps.2023.02.004.
8. **Altman**, D., *How to obtain the P value from a confidence interval*, BMJ, doi:10.1136/bmj.d2304.
9. **Altman (B)** et al., *How to obtain the confidence interval from a P value*, BMJ, doi:10.1136/bmj.d2090.
10. **Amirizadeh** et al., *The effect of remdesivir on mortality and the outcome of patients with COVID-19 in intensive care unit: A case-control study*, Health Science Reports, doi:10.1002/hsr2.1676.
11. **Andreani** et al., *In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect*, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.
12. **Anglemeyer** et al., *Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials*, Cochrane Database of Systematic Reviews 2014, Issue 4, doi:10.1002/14651858.MR000034.pub2.
13. **Arch** et al., *Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study*, medRxiv, doi:10.1101/2021.06.18.21259072.
14. **Arfijanto** et al., *Duration of SARS-CoV-2 RNA Shedding Is Significantly Influenced by Disease Severity, Bilateral Pulmonary Infiltrates, Antibiotic Treatment, and Diabetic Status: Consideration for Isolation Period*, Pathophysiology, doi:10.3390/pathophysiology30020016.
15. **Aweimer** et al., *Mortality rates of severe COVID-19-related respiratory failure with and without extracorporeal membrane oxygenation in the Middle Ruhr Region of Germany*, Scientific Reports, doi:10.1038/s41598-023-31944-7.
16. **Bacigalupo** et al., *Unveiling patenting strategies of therapeutics and vaccines: evergreening in the context of COVID-19 pandemic*, Frontiers in Medicine, doi:10.3389/fmed.2023.1287542.
17. **Barrat-Due** et al., *Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19*, Annals of Internal Medicine, doi:10.7326/M21-0653.
18. **Bavaro** et al., *Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study*, Viruses, doi:10.3390/v15051199.
19. **Behboodikhah** et al., *Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Regimens in Hospitalized Patients in Shiraz*, Iranian Journal of Science and Technology, Transactions A: Science, doi:10.1007/s40995-022-01351-0.
20. **Beigel** et al., *Remdesivir for the Treatment of Covid-19 — Final Report*, NEJM, doi:10.1056/NEJMoa2007764.
21. **Bowen** et al., *Reduction in risk of death among patients admitted with COVID-19 between first and second epidemic waves in New York City*, Open Forum Infectious Diseases, doi:10.1093/ofid/ofac436.
22. **Burhan** et al., *Characteristics and outcomes of patients with severe COVID-19 in Indonesia: Lessons from the first wave*, PLOS ONE, doi:10.1371/journal.pone.0290964.
23. **c19early.org**, [c19early.org/timeline.html](https://c19early.org/timeline.html).
24. **c19early.org (B)**, [c19early.org/treatments.html](https://c19early.org/treatments.html).
25. **Chang** et al., *The association between COVID-19 vaccination and confirmed patients with hospitalization in Omicron era: A retrospective study*, Medicine, doi:10.1097/MD.00000000000036777.
26. **Chew** et al., *Clinical Predictors for Abnormal ALT in Patients Infected with COVID-19—A Retrospective Single Centre Study*, Pathogens, doi:10.3390/pathogens12030473.

27. **Concato** et al., NEJM, 342:1887-1892, doi:10.1056/NEJM200006223422507.
28. **Davidson** et al., *No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study*, Journal of Clinical Epidemiology, doi:10.1016/j.jclinepi.2023.08.011.
29. **De Forni** et al., *Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients*, PLoS ONE, doi:10.1371/journal.pone.0276751.
30. **De Forni (B)** et al., *Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients*, PLoS ONE, doi:10.1371/journal.pone.0276751.
31. **Deaton** et al., *Understanding and misunderstanding randomized controlled trials*, Social Science & Medicine, 210, doi:10.1016/j.socscimed.2017.12.005.
32. **Delandre** et al., *Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants*, Pharmaceuticals, doi:10.3390/ph15040445.
33. **Deng**, H., PyMeta, Python module for meta-analysis, [www.pymeta.com/](http://www.pymeta.com/).
34. **Diaz** et al., *Remdesivir and Mortality in Patients with COVID-19*, Clinical Infectious Diseases, doi:10.1093/cid/ciab698.
35. **Eberhardt** et al., *SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels*, Nature Cardiovascular Research, doi:10.1038/s44161-023-00336-5.
36. **Egger** et al., *Bias in meta-analysis detected by a simple, graphical test*, BMJ, doi:10.1136/bmj.315.7109.629.
37. **El-Solh** et al., *Clinical Course and Outcome of COVID-19 Acute Respiratory Distress Syndrome: Data From a National Repository*, Journal of Intensive Care Medicine, doi:10.1177/0885066621994476.
38. **Elec** et al., *COVID-19 and Kidney Transplantation: The impact of remdesivir on renal function and outcome - a retrospective cohort study*, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.03.015.
39. **Elhadi** et al., *Epidemiology, outcomes, and utilization of intensive care unit resources for critically ill COVID-19 patients in Libya: A prospective multi-center cohort study*, PLoS ONE, doi:10.1371/journal.pone.0251085.
40. **Faria** et al., *Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil*, Science, doi:10.1126/science.abh2644.
41. **Fiaschi** et al., *In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants*, Viruses, doi:10.3390/v16020168.
42. **Flisiak** et al., *Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study*, Polish Archives of Internal Medicine, doi:10.20452/pamw.15735.
43. **Fried** et al., *Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States*, Clinical Infectious Disease, doi:10.1093/cid/ciaa1268.
44. **Garibaldi** et al., *Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19*, medRxiv, doi:10.1101/2020.11.19.20234153.
45. **Gérard** et al., *Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database*, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.2145.
46. **Goldberg** et al., *A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary center in Israel*, Clinical Microbiology and Infection, doi:10.1016/j.cmi.2021.02.029.
47. **Gottlieb** et al., *Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients*, New England Journal of Medicine, doi:10.1056/NEJMoa2116846.
48. **Gøtzsche**, P., *Bias in double-blind trials*, Doctoral Thesis, University of Copenhagen, [www.scientificfreedom.dk/2023/05/16/bias-in-double-blind-trials-doctoral-thesis/](http://www.scientificfreedom.dk/2023/05/16/bias-in-double-blind-trials-doctoral-thesis/).
49. **Hagman** et al., *Effects of remdesivir on SARS-CoV-2 viral dynamics and mortality in viraemic patients hospitalized for COVID-19*, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkad295.



50. **Harbord** et al., *A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints*, *Statistics in Medicine*, doi:10.1002/sim.2380.
51. **Hartantri** et al., *Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia*, *The Lancet Regional Health - Southeast Asia*, doi:10.1016/j.lansea.2023.100167.
52. **Hayden** et al., *Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents*, *New England Journal of Medicine*, doi:10.1056/NEJMoa1716197.
53. **Ho** et al., *A Retrospective Cohort Study Assessing the Impact of Statin Therapy on Hospital Length of Stay and Inpatient Mortality in COVID-19 Patients*, *HCA Healthcare Journal of Medicine*, doi:10.36518/2689-0216.1546.
54. **Ikematsu** et al., *Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts*, *New England Journal of Medicine*, doi:10.1056/NEJMoa1915341.
55. **Jadad** et al., *Randomized Controlled Trials: Questions, Answers, and Musings, Second Edition*, doi:10.1002/9780470691922.
56. **Jamir** et al., *Determinants of Outcome Among Critically Ill Police Personnel With COVID-19: A Retrospective Observational Study From Andhra Pradesh, India*, *Cureus*, doi:10.7759/cureus.20394.
57. **Jeffreys** et al., *Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2*, *International Journal of Antimicrobial Agents*, doi:10.1016/j.ijantimicag.2022.106542.
58. **Jeffreys (B)** et al., *Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2*, *International Journal of Antimicrobial Agents*, doi:10.1016/j.ijantimicag.2022.106542.
59. **Jitobaom** et al., *Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2*, *Research Square*, doi:10.21203/rs.3.rs-941811/v1.
60. **Jitobaom (B)** et al., *Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations*, *BMC Pharmacology and Toxicology*, doi:10.1186/s40360-022-00580-8.
61. **Jittamala** et al., *Clinical antiviral efficacy of remdesivir in COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)*, *The Journal of Infectious Diseases*, doi:10.1093/infdis/jiad275.
62. **Karita** et al., *Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection*, *medRxiv*, doi:10.1101/2021.08.27.21262754.
63. **Kim** et al., *Clinical Outcome and Prognosis of a Nosocomial Outbreak of COVID-19*, *Journal of Clinical Medicine*, doi:10.3390/jcm12062279.
64. **Kneidinger** et al., *Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study*, *Infection*, doi:10.1007/s15010-022-01914-8.
65. **Kumar** et al., *Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial*, *The Lancet Infectious Diseases*, doi:10.1016/S1473-3099(21)00469-2.
66. **Kuno** et al., *The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids*, *Journal of Antimicrobial Chemotherapy*, doi:10.1093/jac/dkab256.
67. **Kurniyanto** et al., *Factors Associated with Death and ICU Referral among COVID-19 Patients Hospitalized in the Secondary Referral Academic Hospital in East Jakarta, Indonesia*, *Journal of Clinical Virology Plus*, doi:10.1016/j.jcvp.2022.100068.
68. **Lee** et al., *Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines*, *Arch Intern Med.*, 2011, 171:1, 18-22, doi:10.1001/archinternmed.2010.482.
69. **Liao** et al., *Clinical characteristics and outcomes among critically ill patients with cancer and COVID-19-related acute respiratory failure*, *BMC Pulmonary Medicine*, doi:10.1186/s12890-024-02850-z.
70. **López-Medina** et al., *Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial*, *JAMA*, doi:10.1001/jama.2021.3071.
71. **Lui** et al., *Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling*, *Virology*, doi:10.1128/mbio.00392-24.

72. **Lv et al.**, *Host proviral and antiviral factors for SARS-CoV-2*, Virus Genes, doi:10.1007/s11262-021-01869-2.
73. **Macaskill et al.**, *A comparison of methods to detect publication bias in meta-analysis*, Statistics in Medicine, doi:10.1002/sim.698.
74. **Madan et al.**, *Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir*, medRxiv, doi:10.1101/2021.07.15.21260600.
75. **Madan (B) et al.**, *Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir*, medRxiv, doi:10.1101/2021.07.15.21260600.
76. **Mahajan et al.**, *Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study*, Indian Journal of Anaesthesia, doi:10.4103/ija.IJA\_149\_21.
77. **Malone et al.**, *Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design*, Nature Reviews Molecular Cell Biology, doi:10.1038/s41580-021-00432-z.
78. **Malundo et al.**, *Predictors of Mortality among inpatients with COVID-19 Infection in a Tertiary Referral Center in the Philippines*, IJID Regions, doi:10.1016/j.ijregi.2022.07.009.
79. **McLean et al.**, *Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial*, Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100.
80. **Mitsushima et al.**, *Risk of Underlying Diseases and Effectiveness of Drugs on COVID-19 Inpatients Assessed Using Medical Claims in Japan: Retrospective Observational Study*, International Journal of General Medicine, doi:10.2147/IJGM.S394413.
81. **Mohd Abd Razak et al.**, *In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds*, Natural Product Communications, doi:10.1177/1934578X231188861.
82. **Moreno et al.**, *Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study*, BMC Medical Research Methodology, doi:10.1186/1471-2288-9-2.
83. **Mozaffari et al.**, *Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: Findings from routine clinical practice.*, Clinical Infectious Diseases, doi:10.1093/cid/ciad460.
84. **Mozaffari (B) et al.**, *Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort*, Clinical Infectious Diseases, doi:10.1093/cid/ciab875.
85. **Mulhem et al.**, *3219 hospitalised patients with COVID-19 in Southeast Michigan: a retrospective case cohort study*, BMJ Open, doi:10.1136/bmjopen-2020-042042.
86. **Muntean et al.**, *Effects of COVID-19 on the Liver and Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta and Non-Delta Variants: An Analysis in a Single Centre*, Pharmaceuticals, doi:10.3390/ph17010003.
87. **Murigneux et al.**, *Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly*, Nature Communications, doi:10.1038/s41467-024-44958-0.
88. **Mustafa et al.**, *Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan*, Exploratory Research in Clinical and Social Pharmacy, doi:10.1016/j.rcsop.2021.100101.
89. **Nadeem et al.**, *Effects of Different Anticoagulation Doses on Moderate-to-Severe COVID-19 Pneumonia With Hypoxemia*, Cureus, doi:10.7759/cureus.43389.
90. **Nichol et al.**, *Challenging issues in randomised controlled trials*, Injury, 2010, doi: 10.1016/j.injury.2010.03.033, www.injuryjournal.com/article/S0020-1383(10)00233-0/fulltext.
91. **Nonaka et al.**, *SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021*, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.08.003.
92. **Ohl et al.**, *Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19*, JAMA Network Open, doi:10.1001/jamanetworkopen.2021.14741.



93. **Oku** et al., *Risk factors for hospitalization or mortality for COVID-19 in patients with rheumatic diseases: Results of a nationwide JCR COVID-19 registry in Japan*, *Modern Rheumatology*, doi:10.1093/mr/roac104.
94. **Olender** et al., *Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care*, *Clinical Infectious Diseases*, doi:10.1093/cid/ciaa1041.
95. **Ong** et al., *A cohort study of COVID-19 infection in pediatric oncology patients plus the utility and safety of remdesivir treatment*, *Acta Oncologica*, doi:10.1080/0284186X.2023.2169079.
96. **Ostrov** et al., *Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells*, *Pathogens*, doi:10.3390/pathogens10111514.
97. **Pasquini** et al., *Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU*, *Journal of Antimicrobial Chemotherapy*, doi:10.1093/jac/dkaa321.
98. **Peacock** et al., *The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry*, *bioRxiv*, doi:10.1101/2021.12.31.474653.
99. **Peters**, J., *Comparison of Two Methods to Detect Publication Bias in Meta-analysis*, *JAMA*, doi:10.1001/jama.295.6.676.
100. **Piccicacco** et al., *Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge*, *Journal of Antimicrobial Chemotherapy*, doi:10.1093/jac/dkac256.
101. **Pourhoseingholi** et al., *Case Characteristics, Clinical Data, And Outcomes of Hospitalized COVID-19 Patients In Qom Province, Iran: A Prospective Cohort Study*, *Research Square*, doi:10.21203/rs.3.rs-365321/v2.
102. **Punzalan** et al., *Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital*, *Frontiers in Immunology*, doi:10.3389/fimmu.2023.1123497.
103. **Raad** et al., *International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship*, *medRxiv*, doi:10.1101/2022.08.25.22279181.
104. **Rothstein**, H., *Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments*, [www.wiley.com/en-ae/Publication+Bias+in+Meta+Analysis:+Prevention,+Assessment+and+Adjustments-p-9780470870143](http://www.wiley.com/en-ae/Publication+Bias+in+Meta+Analysis:+Prevention,+Assessment+and+Adjustments-p-9780470870143).
105. **Rücker** et al., *Arcsine test for publication bias in meta-analyses with binary outcomes*, *Statistics in Medicine*, doi:10.1002/sim.2971.
106. **Said** et al., *The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial*, *Frontiers in Pharmacology*, doi:10.3389/fphar.2022.1011522.
107. **Salehi** et al., *Risk factors of death in mechanically ventilated COVID-19 patients: a retrospective multi-center study*, *Research Square*, doi:10.21203/rs.3.rs-1362678/v1.
108. **Scardua-Silva** et al., *Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19*, *Scientific Reports*, doi:10.1038/s41598-024-52005-7.
109. **Schmidt** et al., *Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19*, *JAMA Network Open*, doi:10.1001/jamanetworkopen.2021.34330.
110. **Seah** et al., *Remdesivir therapy for severe pediatric COVID-19 in Singapore: A single-center retrospective observational cohort study*, *Health Science Reports*, doi:10.1002/hsr2.1698.
111. **Shamsi** et al., *Survival and Mortality in Hospitalized Children with COVID-19: A Referral Center Experience in Yazd, Iran*, *Canadian Journal of Infectious Diseases and Medical Microbiology*, doi:10.1155/2023/5205188.
112. **Siraj** et al., *Efficacy of Various Treatment Modalities on Patient-related Outcome in Hospitalized COVID-19 Patients – A Retrospective Study*, *Indian Journal of Clinical Practice*, 32:9, [ijcp.in/Admin/CMS/PDF/6.%20OriginalResearch\\_IJCP\\_Feb2022.pdf](http://ijcp.in/Admin/CMS/PDF/6.%20OriginalResearch_IJCP_Feb2022.pdf).
113. **Sokolski** et al., *Antiplatelet therapy prior to COVID-19 infection impacts on patients mortality: a propensity score-matched cohort study*, *Scientific Reports*, doi:10.1038/s41598-024-55407-9.

114. **SOLIDARITY Trial Consortium**, Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results, NEJM, doi:10.1056/NEJMoa2023184.
115. **Spinner** et al., Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2020.16349.
116. **Stanley** et al., Meta-regression approximations to reduce publication selection bias, Research Synthesis Methods, doi:10.1002/jrsm.1095.
117. **Sweeting** et al., What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data, Statistics in Medicine, doi:10.1002/sim.1761.
118. **Thairu** et al., A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality, Journal of Pharmaceutical Research International, doi:10.9734/jpri/2022/v34i44A36328.
119. **Treanor** et al., Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial, JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016.
120. **Tsuzuki** et al., Efficacy of remdesivir in hospitalized nonsevere COVID-19 patients in Japan: A large observational study using the COVID-19 Registry Japan, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.02.039.
121. **Ullah** et al., Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore, International Journal of Sciences, doi:10.18483/ijSci.2417.
122. **Vermillion** et al., Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection, Science Translational Medicine, doi:10.1126/scitranslmed.abl8282.
123. **Wan** et al., Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level, Scientific Reports, doi:10.1038/s41598-024-54722-5.
124. **Wang** et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9.
125. **Wilcock** et al., Clinical Risk and Outpatient Therapy Utilization for COVID-19 in the Medicare Population, JAMA Health Forum, doi:10.1001/jamahealthforum.2023.5044.
126. **Willett** et al., The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism, medRxiv, doi:10.1101/2022.01.03.21268111.
127. **Williams**, T., Not All Ivermectin Is Created Equal: Comparing The Quality of 11 Different Ivermectin Sources, Do Your Own Research, doyourownresearch.substack.com/p/not-all-ivermectin-is-created-equal.
128. **Wu** et al., Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS, Frontiers in Pharmacology, doi:10.3389/fphar.2022.692828.
129. **Xu** et al., A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate by UHPLC-Q/TOF-MS and LC-SPE-NMR, Rapid Communications in Mass Spectrometry, doi:10.1002/rcm.9358.
130. **Yang** et al., SARS-CoV-2 infection causes dopaminergic neuron senescence, Cell Stem Cell, doi:10.1016/j.stem.2023.12.012.
131. **Yeramaneni** et al., Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System, Gastroenterology, doi:10.1053/j.gastro.2020.10.011.
132. **Zangeneh** et al., Survival analysis based on body mass index in patients with Covid-19 admitted to the intensive care unit of Amir Al-Momenin Hospital in Arak – 2021, Obesity Medicine, doi:10.1016/j.obmed.2022.100420.
133. **Zavascki** et al., Advanced ventilatory support and mortality in hospitalized patients with COVID-19 caused by Gamma (P.1) variant of concern compared to other lineages: cohort study at a reference center in Brazil, Research Square, doi:10.21203/rs.3.rs-910467/v1.
134. **Zeraatkar** et al., Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review, BMJ Medicine, doi:10.1136/bmjmed-2022-0003091.

135. **Zhang** et al., *What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes*, JAMA, 80:19, 1690, doi:10.1001/jama.280.19.1690.
136. **Zhou** et al., *Acute Kidney Injury and Drugs Prescribed for COVID-19 in Diabetes Patients: A Real-World Disproportionality Analysis*, Frontiers in Pharmacology, doi:10.3389/fphar.2022.833679.